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19 Abstract: Delayed-type, T-cell mediated, drug hypersensitivity reactions are a serious unwanted 
20 manifestation of drug exposure that develops in a small percentage of the human population. Drugs 
21 and drug metabolites are known to interact directly and indirectly (through irreversible protein 
22 binding and processing to the derived adducts) with HLA proteins that present the drug-peptide 
23 complex to T-cells. Multiple forms of drug hypersensitivity are strongly linked to expression of a single 
24 HLA allele and there is increasing evidence that drugs and peptides interact selectively with the protein 
25 encoded by the HLA allele. Despite this, many individuals expressing HLA risk alleles do not develop 
26 hypersensitivity when exposed to culprit drugs suggesting a non-linear, multifactorial relationship in 
27 which HLA risk alleles are one factor. This has prompted a search for additional susceptibility factors. 
28 Herein, we argue that immune regulatory pathways are one key determinant of susceptibility. As 
29 expression and activity of these pathways is influenced by disease, environmental and patient factors, 
30 it is currently impossible to predict whether drug exposure will result in a health benefit, 
31 hypersensitivity or both. Thus, a concerted effort is required to investigate how immune dysregulation 
32 influences susceptibility towards drug hypersensitivity. 
33
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36 Drug hypersensitivity refers to objectively reproducible symptoms or signs initiated by exposure to a 
37 drug at a dose normally tolerated by non-hypersensitive persons (1). Hypersensitivity is also 
38 commonly referred to as a form of off-target toxicity, which means that the development of tissue 
39 injury is not predictable from known pharmacology of the drug and there is no simple association 
40 between the dose of the drug administrated and the development of clinical signs and symptoms. 
41 Delayed-type reactions vary in severity and can target individual organs such as liver and skin in 
42 isolation or as part of a generalized hypersensitivity syndrome. Common to the cellular 
43 pathophysiology of drug hypersensitivity is the presence of drug-specific T-lymphocytes in blood and 
44 inflamed tissue (2-4). In fact, cutaneous hypersensitivity reactions (maculopapular, pustular, and 
45 bullous) are classified according the effector molecules secreted by T-cells when activated with drugs 
46 (5, 6).
47 In 2002, Mallal et al. reported a strong association between the presence of HLA-B*57:01, HLA-DR7, 
48 and HLA-DQ3 and hypersensitivity to the HIV-1 reverse-transcriptase inhibitor abacavir (7). 
49 Subsequent studies demonstrated that (i) all skin test confirmed cases of abacavir hypersensitivity 
50 carry HLA-B*57:01 (8), (ii) abacavir interacts selectively with high affinity within the HLA-B57:01 
51 peptide binding cleft through non-covalent interactions (9-11), and (iii) abacavir only activates CD8+ 
52 T-cells (12-14). It is important to note that the abacavir association differs from all other forms of HLA-
53 linked hypersensitivity reaction. For example, drug-responsive CD4+ and CD8+ T-cells are observed in 
54 patients hypersensitive to drugs such as carbamazepine, dapsone, flucloxacillin who express the 
55 relevant HLA class I risk alleles, B*15:02, B*13:01 and B*57:01, respectively (15-17). These data 
56 indicate that although there is a preference for drug (parent drug, metabolite) peptide complex HLA 
57 T-cell receptor binding in patients, binding interactions are generally heterogeneous and this 
58 contributes to the complete adaptive drug-specific T-cell response. Throughout this manuscript we 
59 discuss the different forms of drug HLA interaction in detail highlighting similarities and differences in 
60 pathways that lead to T-cell activation. However, we subsequently use the general term “drug peptide 
61 complex” where appropriate to refer to any drug-derived structure that interacts with HLA proteins 
62 and T-cell receptors to trigger T-cell activation. This is because the formation of an HLA, drug, peptide 
63 and T-cell receptor complex is necessary for all pathways of T-cell activation. It is simply the nature of 
64 the complex and form of binding interaction that differs. As the number of associations between drug 
65 hypersensitivity and HLA allele expression increases (18-20), it is important to consider the additional 
66 patient factors that confer susceptibility. This is of particular importance because not all patients 
67 expressing a risk HLA are susceptible, while many patients lacking known risk alleles go on to develop 
68 hypersensitivity when exposed to culprit drugs. 































































69 Three factors are critical for the activation of T-cells with drugs; exposure to a drug peptide complex, 
70 the availability of a T-cell repertoire for a drug peptide complex and a protein encoded by HLA alleles 
71 for drug peptide complex binding. The argument is presented that although each factor detailed above 
72 is critical for drug immunogenicity; separately or together, they cannot be used to predict patient 
73 outcome following drug exposure. We hypothesize that when each factor is present, active immune 
74 regulatory pathways (co-inhibitory receptors, Tregs, cytokines) are key determinants of whether drug 
75 exposure will result in hypersensitivity. Since expression and activity of these regulatory pathways are 
76 altered by disease, the genetic make-up of the host and environmental factors, it is currently 
77 impossible to predict whether drug exposure will result in a health benefit, hypersensitivity or both 
78 (Figure 1).  
79
80 Different manifestations of drug hypersensitivity
81 Drug-induced cutaneous reactions: Although skin rashes are common forms of drug hypersensitivity, 
82 serious and life-threatening reactions develop much less frequently. Examples of serious cutaneous 
83 hypersensitivity reactions include Stevens-Johnson syndrome, toxic epidermal necrolysis and drug 
84 reaction with eosinophilia and systemic symptoms (DRESS). Although less serious than the conditions 
85 listed above, acute generalised exanthematous pustulosis and maculopapular exanthema are also 
86 important adverse drug reactions. A broad spectrum of different drugs may cause cutaneous reactions 
87 including the sulfonamides, allopurinol, carbamazepine, dapsone and many of the penicillins (21-24) . 
88 Although there is some degree of pathophysiological overlap, there are some clinically defining 
89 features for each type of severe cutaneous adverse drug reaction and these are briefly discussed 
90 below. 
91 The most common skin manifestation is maculopapular exanthema which accounts for approximately 
92 95% of all cutaneous reactions (25). These are reported as eruptions starting on the trunk and upper 
93 extremities and progressively become more prevalent. These reactions are not life-threatening and 
94 almost always subside when the culprit drug has been withdrawn (26). Antibiotics and a number of 
95 tuberculosis medications such as rifampicin, isoniazid, pyrazinamide and ethambutol are common 
96 causes of maculopapular exanthema (27).
97 Acute generalised exanthematous pustulosis represents a more severe, usually drug-related skin 
98 reaction characterised by the presence of sterile pustules on an erythematous surface along with fever 
99 and neutrophilia in a patient. Furthermore, the involvement of activated neutrophils along with 
100 excessive production of cytokines IL-8 and IL-17 is characteristic of acute generalised exanthematous 
101 pustulosis, stimulating the recruitment to tissues and the induction of innate immune responses (28).































































102 DRESS is a severe skin reaction with an incidence of between 1:1000 and 1:10000 in patients exposed 
103 to culprit drugs such as anticonvulsants, antimicrobials and antivirals (29). The reaction is 
104 characterised by skin eruptions, fever as well as symptoms in other organs, such as hepatitis, nephritis 
105 and thyroiditis (30). DRESS has been shown to be regulated by the cellular actions of eosinophils 
106 mediated via the secretion of IL-5 from drug-specific T-cells (31). Furthermore DRESS is often 
107 associated with reactivation of several viruses, including HHV-6, CMV and EBV (32) (33). 
108 Stevens-Johnson syndrome and toxic epidermal necrolysis define increasing degrees of severity of the 
109 same skin disease and are often grouped together. The disease involves the mucosal membranes 
110 including the eyes, mouth and genitals (30). The level of skin detachment can be used to categorise 
111 the severity of the reaction. The clinical definition of Stevens-Johnson syndrome is when the 
112 detachment of epidermal sheets remains on small areas and occurs on less than 10% of the body 
113 surface area. Stevens-Johnson syndrome/toxic epidermal necrolysis overlap is when this value is 
114 between 10-30% and toxic epide mal necrolysis patients experience large sheets of skin detachment 
115 exceeding 30% of the body surface area (34).
116 Drug-induced liver injury: The liver is the largest organ in humans; it is the major organ responsible for 
117 the metabolism and detoxification of drugs. Hepatocytes (parenchymal cells) make up about 85% of 
118 the liver while non-parenchymal cells, including liver sinusoidal endothelial cells, hepatic stellate cells, 
119 Kupffer cells and biliary epithelial cells make up the remaining 15% and play important roles in 
120 maintaining the homeostasis of the liver. Drug-induced liver injury is a major reason for drug attrition 
121 and withdrawal of drugs in clinical trials or drugs already licenced for clinical use (35). Worldwide, the 
122 estimated annual incidence rate of drug-induced liver injury is 0.02% (36, 37). Hoofnagle and 
123 Björnsson have recently classified drug-induced liver injury into three categories (direct, 
124 indirect and idiosyncratic) according to frequency, predictability and reaction mechanisms 
125 (38). Direct liver injury is common and occurs rapidly when drugs are given at high doses (e.g., 
126 paracetamol). Indirect liver injury has an intermediate frequency, is partially predictable and 
127 occurs as an indirect action of the drug on liver or the immune system (e.g., monoclonal 
128 antibodies). Finally, idiosyncratic liver injury occurs in only a small number of individuals, is 
129 not predictable and involves activation of the patients adaptive immune system. The mean 
130 onset of idiosyncratic liver injury with certain drugs exceeds 100 days (39). Amoxicillin, clavulanic acid, 
131 NSAIDS, flucloxacillin, lapatinib, lumiracoxib, ximelagatran among other drugs have been implicated 
132 with various degrees of unpredictable/idiosyncratic liver injury. Several forms of drug-induced liver 
133 injury are strongly associated with expression of specific HLA alleles (40). This, alongside the delayed 
134 onset of clinical symptoms, is indicative of the pathogenesis involving drug-specific T-cells. Recent 































































135 studies have identified and characterized drug-responsive CD4+ and CD8+ T-cells from the peripheral 
136 blood of patients with tuberculosis medicine-, co-amoxiclav- and flucloxacillin-induced liver injury (41-
137 43). Furthermore, T-cells have been shown to infiltrate liver and kill hepatocytes through the release 
138 of cytolytic molecules (44, 45).    
139
140 Does drug exposure impact on susceptibility to hypersensitivity?
141 For this discussion, we assume that the initiating event for T-cell activation is either a drug or drug 
142 metabolite binding directly to the HLA T-cell receptor complex (through either covalent or non-
143 covalent binding) or a drug or drug metabolite binding indirectly to non-HLA proteins (through 
144 covalent binding; the HLA binding epitope being a peptide derived from the modified protein, which 
145 may or may not contain the drug moiety).   
146 In consideration of the latter first, most research has been conducted on biological samples from 
147 patients with -lactam hypersensitivity. For adduct formation, the β-lactam ring is targeted by lysine 
148 residues. Nucleophilic attack leads to ring opening and binding of the penicilloyl group to the lysine 
149 residue (46). -lactam antibiotics modify serum proteins such as serum albumin and multiple 
150 intracellular proteins (47-51). Protein adducts are transported to antigen presenting cells via exosomal 
151 transport (50, 52) and -lactam-modified protein and peptide adducts have been shown to activate 
152 patient T-cells (15, 53-57). Importantly, these adducts are formed in all drug exposed patients (48, 58-
153 60), those who develop skin and liver reactions as well as those that safely tolerate the drug. 
154 Moreover, through the synthesis of -lactam-modified peptides as standards for mass spectrometric 
155 analysis, Meng et al (58) were able to quantify and compare the level of drug albumin binding in 
156 hypersensitive and tolerant patients. No clear differences in the level of -lactam antibiotic lysine 
157 modification was detected between the two patient groups, and importantly, the level of modification 
158 in all patients exceeded the threshold required for activation of -lactam antibiotic-responsive T-cells. 
159 Obviously, additional studies are required to explore whether hapten thresholds are exceeded in 
160 patients receiving others -lactam antibiotics and hapteneic drug metabolites. However, currently 
161 available data suggests that although the formation of drug protein adducts may be an important, if 
162 not critical factor for drug immunogenicity, the level of therapeutic drug exposure does not seem to 
163 be a key determinant of patient outcome. One way to confirm this would be a detailed comparison of 
164 the incidence of hypersensitivity reactions in patients receiving higher and lower -lactam doses or 
165 longer and shorter treatment courses, as long as this doesn’t impact on clinical care.   
166 An assortment of drug structures activate T-cells through a direct non-covalent interaction with HLA 
167 and/or specific T-cell receptors. The p-I concept has been coined to explain this phenomenon and 































































168 differentiate this pathway of T-cell activation from the hapten concept. A number of pieces of 
169 experimental evidence support this direct binding concept: first, the addition of parent drug to human 
170 immune cell culture systems that express low levels of drug metabolizing enzymes leads to a T-cell 
171 response characterized by proliferation and cytokine and cytolytic molecule release (61-63); second, 
172 inhibition of protein processing within antigen presenting cells, which blocks T-cell responses to 
173 protein antigens has no effect on the activation of T-cells with drugs (64, 65); and third, the kinetics of 
174 T-cell activation with drugs is rapid, within minutes (14, 66), which is in stark contrast to classical 
175 antigen presentation pathways that require several hours. Many drugs have been shown to activate 
176 T-cells from hypersensitive patients via this pathway, including sulfamethoxazole (65), carbamazepine 
177 (67, 68) and allopurinol (66). However, with the exception of abacavir, the nature of the drug peptide 
178 HLA T-cell receptor interaction is yet to be defined. The selective interaction of abacavir with HLA-
179 B*57:01 alters the spatial arrangement of molecules within the peptide binding groove. This results in 
180 the display of novel “altered” HLA-B*57:01 peptide sequences that seemingly go on to stimulate T-
181 cells that bring about abacavir hypersensitivity (9-11, 69). Adam et al. (69) demonstrated that 
182 abacavir-responsive T-cells stemming from naïve and memory compartments are detectable in 100% 
183 of donors expressing HLA-B*57:01. This led the authors to suggest that abacavir T-cell reactivity by-
184 passes normal co-stimulatory/regulatory requirements. However, we draw readers attention to the 
185 fact that it has not been possible to explain why only half of HLA-B*57:01+ donors (who all possess 
186 abacavir-responsive T-cells) exposed to abacavir develop hypersensitivity. It should also be noted that 
187 p-I- and hapten-responsive T-cells are not always detected in isolation. For the -lactam antibiotics 
188 (55, 70) and sulfonamides/sulfones (17, 71, 72), the only drug exemplars studied to date, drug p-i- and 
189 hapten-responsive T-cells are found together. 
190 Drugs administered at a high mass dose more frequently cause hypersensitivity reactions, when 
191 compared with drugs administered at lower doses (73). However, in humans, individual drugs tend to 
192 be administered at similar doses using dosing regimens directed to achieve drug concentrations within 
193 a therapeutic window for a sustained duration of time. Humans are therefore exposed to similar 
194 plasma concentrations of the parent drug. A handful of studies describe associations between 
195 metabolism (increased production of metabolite or increased exposure to parent drug) and the 
196 incidence of drug hypersensitivity reactions (74). For example, CYP2C9*3, which decreases phenytoin 
197 clearance is associated with an increased occurrence of anticonvulsant hypersensitivity (75, 76). 
198 Similarly, impaired renal function and increased plasma levels of oxypurinol (the metabolite that 
199 drives T-cell responses in hypersensitive patients (77)) correlate with the poor prognosis of 
200 allopurinol-induced severe cutaneous hypersensitivity reactions (78). However, these findings seem 































































201 to be an exception, rather than a rule, as few other studies have reported associations between drug 
202 disposition and hypersensitivity. 
203 It is clear that a threshold level of drug exposure must be surpassed for the activation of T-cells. In 
204 agreement with this, most drugs that have been withdrawn from the market or have received black 
205 box warnings due to liver injury are administered at daily doses greater than 50 mg per day (79, 80).  
206 However, it is difficult to argue susceptibility to drug hypersensitivity is solely dependent upon plasma 
207 drug concentrations or the drug concentration at the site of T-cell activation. The vast majority of 
208 patients tolerate therapeutics drug concentrations with little or no adverse effects. Thus, for the 
209 purpose of this review we argue that everyone taking medicinal drugs may be exposed to therapeutic 
210 concentrations that are capable of forming HLA drug peptide complexes and delivering them to T-
211 cells. 
212
213 Does the display of drug peptide complexes by human leukocyte antigen proteins impact on 
214 susceptibility to hypersensitivity?
215 A plethora of studies, starting with abacavir discussed above, have identified astonishingly strong 
216 associations between HLA class I alleles and susceptibility to drug hypersensitivity reactions, which 
217 implies a direct effect of the gene product on the disease (81, 82) (Table 1 shows several HLA class I 
218 allele-associated drug hypersensitivity reactions with known drug peptide complex HLA binding 
219 interactions for T-cell activation). This suggests that mechanistically, restriction of the fit of the drug 
220 and peptide into HLA proteins is important for T-cell activation. HLA-B*57:01, which is associated with 
221 abacavir hypersensitivity, has a positive predictive value of 55 % and a negative predictive value of 
222 100 % (8). This means that only individuals carrying the allele are at risk and 1 out of 2 carriers develop 
223 hypersensitivity following abacavir exposure. Genetic screening prior to abacavir use is routine 
224 practice and eradicates the appearance of hypersensitivity. Other forms of HLA class I associated 
225 hypersensitivity (e.g., flucloxacillin [HLA-B*57:01] (83), allopurinol [HLA-B*58:01] (21), carbamazepine 
226 [HLA-B*15:02] (84) and dapsone [HLA-B*13:01] (85)) display similar negative predictive values (99-
227 100%) in specific patient groups; however, the positive predictive value is much lower. This suggests 
228 that the HLA allele is essential for drug peptide complex display, but other factors determine whether 
229 drug exposure results in a T-cell response and hypersensitivity. In a final group of HLA class I associated 
230 reactions (e.g., carbamazepine [HLA-A*31:01] (86), co-amoxiclav [HLA-A*02:01] (87), 
231 sulfamethoxazole [HLA-B*38:02] (88), minocycline [HLA-B*35:02] (89) and terbinafine [HLA-A*33:01] 
232 (90)), the carrier frequency in hypersensitive patients is 50% or lower. Thus, in these reactions, the 
233 drug-peptide complex is displayed by a number of different HLA proteins to activate T-cells. Additional 































































234 forms of drug hypersensitivity are (i) linked to expression of HLA class II allele(s) or (ii) not known to 
235 be associated with expression of a specific HLA allele despite the fact that drug-specific CD4+ and CD8+ 
236 T-cells are detectable. Importantly, it has not been possible to show that selective drug peptide 
237 complex binding to HLA class II proteins, identified as risk factors, leads to the activation of CD4+ T-
238 cells (authors unpublished data). 
239 Drug-peptide complex HLA protein binding is without doubt critical for the development of drug 
240 immunogenicity; however, from the above discussion it is clear that for most HLA allele associated 
241 reactions, expression of the HLA protein alone does not determine whether drug exposure will result 
242 in hypersensitivity.
243          
244 Does expression of specific T-cell receptors impact on susceptibility to hypersensitivity?
245 Advances in high-throughput sequencing technologies has enabled the detailed analysis of global T-
246 cell repertoires in patients with and without immunological diseases. Glanville et al. (91) recently 
247 defined the minimal requirements for T-cell receptor specificity through an analysis of T-cell receptor 
248 sequences using a panel of HLA binding peptides. Focussing on 5711 T-cell receptor V chain 
249 sequences from CD4+ T-cells derived from 22 donors with mycobacterium tuberculosis, they identified 
250 141 T-cell receptor specificity groups including 16 groups containing T-cell receptors from at least 3-4 
251 individuals with shared alleles. The T-cell receptors shared HLA alleles from different donors for shared 
252 peptide presentation. These data indicate that a diverse array T-cell receptor sequences are available 
253 in any individual that interact with peptide ligands from a single protein antigen. Similar technologies 
254 should be applied to the study of drug hypersensitivity to explore whether shared drug peptide 
255 complex specificity clusters are present across different donors and whether this correlates with 
256 disease. 
257 Our knowledge of how T-cell receptor sequences impact on drug hypersensitivity is in its infancy. 
258 Through global expression level analysis and assessment of the third complementary-determining 
259 region length distribution of the T-cell receptor profile in patients with carbamazepine-induced 
260 Stevens-Johnson syndrome, Ko et al. (92) identified VB-11-ISGSY as a dominant clonotype shared 
261 amongst different hypersensitive, but not drug-tolerant, donors. Furthermore, carbamazepine-
262 specific cytotoxic T-cells could be primed from PBMC of healthy human donors that were carriers of 
263 both HLA-B*15:02 and VB-11-IsGSY. More recently, the same group working on the same patient 
264 cohort reported the detection of a public T-cell receptor composed of paired TCRα CDR3 “VFDNTDKLI” 
265 and TCRβ CDR3 “ASSLAGELF” clonotypes and that similar receptor clusters are found in the blister 
266 fluid cells and peripheral blood (93). These data suggest that the correct combination of HLA, drug 































































267 peptide complex and T-cell receptor may be important drivers for carbamazepine-induced Stevens-
268 Johnson syndrome. Unpublished data analysing blister fluid from a different cohort of patients with 
269 Stevens Johnson syndrome after administration of multiple drugs also show an enrichment of T-cells 
270 that display a selective repertoire of T-cell receptor sequences at the most early phase of the adverse 
271 event (Vocanson, personal communication). However, the T-cell receptor identified differs across 
272 patients, even those exposed to the same culprit drug. Moreover, a dominant clonotype was not 
273 detected in all patients. 
274 The proposal that susceptibility to drug hypersensitivity relates to expression of a single T-cell 
275 clonotype contrasts with published literature showing the polyclonal expansion of T-cells by certain 
276 drugs. Abacavir, which interacts non-covalently with HLA-B*57:01, activates T-cells in 100% of human 
277 donors that carry the risk allele (even though only half develop hypersensitivity when exposed to 
278 abacavir) (94). Analysis of T-cell receptors expressed on abacavir-responsive T-cells did not reveal 
279 skewed patterns (9). This is consistent with abacavir activating an array of different T-cell receptors. 
280 Similarly, nitroso sulfamethoxazole, a cysteine-reactive metabolite of sulfamethoxazole has been 
281 shown to prime naïve CD4+ and CD8+ T-cells from 59/60 healthy human donors (95, 96). Spectratyping 
282 revealed that nitroso-sulfamethoxazole-specific T-cell responses were controlled by public T-cell 
283 receptors present in all individuals alongside p ivate T-cell repertoires specific to each individual (97). 
284 Finally, elegant studies by Azoury et al. (98, 99) utilized immunodominant -lactam-modified peptides 
285 derived from albumin to calculate the frequency of naïve CD4+ T-cells that recognize the drug peptide 
286 complex. The haptenated peptides were recognized by naïve T-cells from 13/14 human donors. 
287 These data, although utilizing a limited number of drugs, cover three forms of drug HLA binding 
288 derivative  (parent drug, drug metabolite and haptenated peptide) and show that PBMC from each 
289 and every one of us contain naïve T-cells capable of recognizing and responding to drugs. Although 
290 certain HLA drug peptide complexes may associate preferentially with specific T-cell receptors and this 
291 may impact on the development of hypersensitivity: as has been described with HLA-B*15:02 and 
292 patients with carbamazepine-induced Stevens Johnson syndrome. It needs to be emphasized that the 
293 Caucasian population very rarely express HLA-B*15:02; they do however still develop carbamazepine 
294 hypersensitivity. The only explanation for this is that carbamazepine interacts with multiple HLA 
295 proteins and T-cell receptors to bring about hypersensitivity reactions.    
296
297 To summarize the discussion thus far, most, if not all, drug-treated patients have a T-cell repertoire 
298 for drug peptide complexes and are exposed to drugs in sufficient quantities to activate the T-cells. 
299 Although expression of a specific HLA protein is important, for many forms of hypersensitivity, HLA 































































300 risk allele expression per se does not predict the outcome of drug exposure. Therefore, for the 
301 remainder of this article we focus on the hypothesis that immune regulatory pathways are key 
302 determinants of whether drug exposure in genetically predisposed individuals will result in 
303 hypersensitivity. Figure 2 illustrates that drug exposure, expression of HLA alleles and T-cell receptors 
304 are all important determinants of immunogenicity, whereas regulatory pathways are determinants of 
305 hypersensitivity. The pathways of drug-specific T-cell activation are also depicted with reference to 
306 the possible different requirements for immune regulation. 
307 While immune cells survey the tissue microenvironment for drug-derived signals, a key task is to 
308 maintain tissue homeostasis. The outcome of immune surveillance may be unresponsiveness (the 
309 immune system does not detect the drug-derived signal), a conventional effector response (leading 
310 to hypersensitivity with a drug-derived signal) or tolerance (a state of immunological 
311 unresponsiveness to the drug-derived signal). Tolerance can be natural or induced and these terms 
312 are discussed in more detail below with reference to regulatory T-cells. In the context of drug 
313 hypersensitivity it is important to consider variation in natural tolerance and whether drug treatment 
314 actively induces or alters toleragenic pathways and indeed the potential for certain drug peptide 
315 complexes to bypass natural tolerance.  The way the immune system regulates immune responses, 
316 and is able to adapt to change, is through the expression of an array of cell surface co-stimulatory and 
317 co-inhibitory signalling receptors (Figure 3). Co-stimulatory receptors collect information from 
318 stressed or damaged cells and tissue and determine whether an effector response should be directed 
319 towards an antigen. The co-inhibitory receptors act alongside regulatory T-cells (Tregs) and 
320 stimulatory and inhibitory cytokines (e.g., IL-10, TGF-) to preserve the regulatory environment to 
321 prevent unwanted immune responses against self and non-damaging agents and to prevent excessive 
322 responses to antigens when a T-cell response has been initiated. Factors that influence the balance 
323 between co-stimulatory and co-inhibitory signalling include the genetics of the host, disease and 
324 environmental factors. 
325 It is possible that each and every one of us may develop a hypersensitivity reaction following drug 
326 treatment if the balance between co-stimulation and co-inhibition is skewed at the time of exposure. 
327 This represents a frightening concept for Pharma and healthcare professionals, since the factors that 
328 control this balance are difficult to predict and will vary across individuals and within an individual 
329 when they are exposed to different immunomodulatory environments (e.g., infections or damaging 
330 agents). For this reason, although it might be possible to work towards a framework to predict the 
331 intrinsic immunogenicity of a drug, prediction of the number of individuals that will ultimately develop 
332 a clinical drug hypersensitivity reaction is very difficult.            































































333           
334 Clinical evidence to exclude drug exposure, the availability of a T-cell repertoire or a single genetic 
335 factor as key determinants that impact on susceptibility to drug hypersensitivity 
336 We have worked together with respiratory physicians to understand the chemical and cellular basis 
337 of -lactam hypersensitivity in patients with cystic fibrosis. This patient population is an important 
338 study group as they have been monitored closely throughout childhood and adult life and as such they 
339 have almost complete drug histories as well as detailed records of the nature and timeframe of 
340 hypersensitivity reactions that occur more frequently when compared to the general population (100-
341 102). Piperacillin is a commonly used -lactam antibiotic for the treatment of recurrent respiratory 
342 infections. Patients receive repeated courses of the drug at the same dose (12g/day; iv injection) and 
343 duration (14 days). If one assumes that a patient receives 3 treatment courses a year, the overall mass 
344 of piperacillin a patient will be exposed to over a 20 year period would exceed 10kg. Thirty five percent 
345 of patients with cystic fibrosis develop delayed-type piperacillin hypersensitivity reactions 
346 characterized clinically with maculopapular or urticarial rashes, fever and arthralgia (100). Drug-
347 responsive T-cells are detected in approximately 75% of hypersensitive patients, but not tolerant 
348 controls using the lymphocyte transformation test (60). Moreover, CD4+ and CD8+ T-cells that secrete 
349 proinflammatory cytokines, including IL-22 and cytolytic molecules, when exposed to piperacillin are 
350 present in inflamed skin (2). Drug-responsive T-cells are also detectable in drug tolerant patients 
351 (unpublished data) and drug-naïve donors (2, 96), but only when immune regulation has been 
352 perturbed ex vivo and the drug peptide adduct is presented by dendritic cells pre-treated with LPS to 
353 provide co-stimulation.
354 The mean time to onset of piperacillin hypersensitivity is the ninth day of the ninth treatment course 
355 (i.e., the average patient will tolerate eight separate courses of piperacillin), which might lead one to 
356 assume that susceptibility is linked to accumulation of, or repeated exposure to, the drug peptide 
357 complex. However, over a 20 year assessment period at the St. James Cystic Fibrosis Unit (Leeds, UK) 
358 patients have been diagnosed with hypersensitivity after every treatment course (1-15; personnel 
359 communication, Dr Paul Whitaker). These clinical data are impossible to rationalize in terms of drug 
360 exposure/accumulation, the availability of a T-cell repertoire for the drug peptide complex or indeed 
361 a single genetic factor such as HLA. 
362 As depicted in figure 2, the pathway of T-cell activation for drugs such as allopurinol and 
363 carbamazepine are very different to that of -lactam antibiotics. It is possible that reactions with these 
364 drugs occur after T-cell responses develop in the presence of other classical peptide antigens (i.e., the 
365 drug peptide complex cross-reacts with the peptide antigen). In this case, the drug will not always 































































366 activate a de novo response for hypersensitivity to develop and the regulatory requirements for 
367 activation will be lower. The caveat to this argument however is that both of these drugs have been 
368 shown to prime naïve T-cells using autologous dendritic cells to present the drug peptide complex in 
369 an appropriate immunological form (103).    
370 The immune regulatory network
371 Several mechanisms have evolved to regulate T-cell responses and prevent the development of 
372 autoimmune disease and other inflammatory conditions. The best known mechanisms of peripheral 
373 tolerance include thymic selection of T-cells, the suppressive activity of Tregs (104) and the increased 
374 expression of cell surface receptors, the so-called immune checkpoints (105, 106). The importance of 
375 immune regulation and power of the regulatory network has been demonstrated clinically through 
376 the application of immune checkpoint inhibitors for the treatment of cancer (107). Furthermore, 
377 mutations in FOXP3, the regulatory transcription factor for Tregs, results in dysfunctional Tregs and 
378 the development of autoimmune disease and allergy (108). IPEX syndrome – a loss of function 
379 mutation in FOXP3 (and other regulatory pathways such as CTLA4) - is the most extreme clinical 
380 scenario. IPEX syndrome is often fatal presenting clinically for a variety of autoimmune-like 
381 syndromes. It would be interesting to investigate whether patients with IPEX syndrome also develop 
382 more drug hypersensitivity reactions. Tregs are now easy to expand ex vivo and have been used in 
383 Phase I clinical trials for the treatment of autoimmune disease to prevent transplant rejection (109). 
384 In the following sections we briefly discuss the major immune regulatory pathways and how 
385 dysregulation of these pathways may impact on drug hypersensitivity. 
386
387 Immune checkpoints     
388 Immune checkpoints are a series of receptor ligand interactions between T-cells and antigen 
389 presenting/tissue cells which specifically co-ordinate the secondary co-stimulatory signal required for 
390 immune activity following TCR binding. Checkpoint proteins negatively regulate the activation of naïve 
391 T-cells. Furthermore, checkpoint receptor expression is upregulated on T-cells when they are 
392 activated, providing a negative feedback loop to restrict the effector response. PD-1 and CTLA-4, which 
393 are expressed on T-cells, are the most studied immune checkpoints. PD-1 interacts with ligands PD-L1 
394 and PD-L2, which activates tyrosine phosphatases that inactivate tyrosine kinase-mediated activation 
395 signals (110). CTLA-4 binds to ligands CD80 and CD86 on antigen presenting cells displaying antigen. 
396 T-cell inhibition is achieved through competitive antagonism of CD28 signalling and direct delivery of 
397 an intracellular signal (111). Other less well characterized immune checkpoints include TIM-3 































































398 (suppresses Th1/Th17 CD4+ responses (112)) and LAG-3 (contributes towards Treg activity and directly 
399 suppresses CD8+ T-cells (113)). The complex interaction between immune checkpoints and naïve and 
400 memory T-cell subsets and how intra- and inter-individual variation impacts on susceptibility to 
401 adverse immunological reactions is ill-defined. 
402 In recent years, we have investigated whether receptor blockade with immune checkpoint inhibitors 
403 remove the immune brakes and enhance the priming of naïve T-cells by drugs. Naïve T-cells were 
404 cultured in vitro with drug and autologous dendritic cells in the presence and absence of immune 
405 checkpoint inhibitors targeting PD-1, CTLA-4 and Tim-3 for 14 days to allow priming to occur. Drug 
406 exposure was associated with an increase in expression of all three immune checkpoints on dividing 
407 T-cells during the culture period, presumably a regulatory event to keep the drug-specific response in 
408 check (114). After the 14 day culture period, the primed T-cells were restimulated with drug and a 
409 second batch of autologous dendritic cells and the strength of the T-cell response was assessed. PD-1 
410 and CTLA-4 block enhanced the priming of naïve T-cells to drugs, whereas Tim-3 block had no effect 
411 (97, 114). A similar effect (enhanced priming of naïve T-cells to drugs) has been demonstrated in vivo 
412 with PBMC from patients receiving immune checkpoint inhibitor therapy (unpublished data). 
413 Furthermore, it is becoming apparent that patients receiving immune checkpoint inhibitor therapy 
414 develop more frequent drug hypersensitivity reactions. Ford et al. (115) recently described the 
415 development of sulfasalazine (a combination of salicylic acid and sulfapyridine)-induced cutaneous 
416 hypersensitivity in 4 patients with metastatic melanoma that had previous been treated with the anti 
417 PD-1 inhibitor pembrolizumab or the anti CTLA-4 inhibitor ipilimumab. Presumably the T-cell response 
418 and subsequent hypersensitivity reaction was induced by the sulfonamide component of sulfasalazine 
419 when natural immune checkpoints had been suppressed. Phillips et al. have recently reported on the 
420 treatment  outcomes of 285 patients that developed cutaneous adverse events attributed to immune 
421 checkpoint inhibitor therapy (116). It would be interesting to consider the number of these patients 
422 receiving concomitant therapy with low molecular weight drugs.  
423 A report of the post-approval safety of the B-raf inhibitor vemurafenib described seven patients that 
424 developed serious cutaneous hypersensitivity reactions and importantly, six of these patients received 
425 anti-PD-1 antibody therapy prior to starting vemurafenib (117). Phase II studies of ipilimumab plus or 
426 minus dacarbazine therapy concluded that ipilimumab monotherapy had a manageable adverse 
427 events profile (118), while dual therapy provided no improvement in efficacy and was not tolerable 
428 due to serious liver injury (119). Dacarbazine use alone is only associated with rare cases of liver injury 
429 (120). The immune checkpoint inhibitor again seems to alter the co-stimulatory/co-inhibitory balance, 
430 permitting the development of dacarbazine-induced liver injury in almost all treated patients. Finally, 
431 it has been reported that polymorphisms in regulatory targets of immune responses such as CTLA-4 































































432 and IL-10 could modulate susceptibility to nonsteroidal anti-inflammatory drug (121) and efavirenz 
433 (122) hypersensitivity reactions. Collectively, these data indicate that immune checkpoints act to 
434 regulate the strength of the drug-specific T-cell response and hence impact on the balance between 
435 tolerance and hypersensitivity (Figure 4). These interactions will become increasingly relevant as the 
436 focus on combination therapies for the treatment of various malignancies increases. Combination 
437 therapies in oncology started by using two checkpoint inhibitors in combination (αCTLa-4/αPD-1) 
438 which illustrated increased efficacy but also an increased incidence of toxicity with a severe toxicity 
439 incidence of 56% of patients (123). Latterly there have been an increasing number of trials combining 
440 checkpoint inhibitors with additional systemic anticancer therapies including chemotherapy 
441 (KEYNOTE189 [ClinicalTrials.gov number, NCT02578680], IMpassion150 [ClinicalTrials.gov 
442 number, NCT03125902]) and tyrosine kinase inhibitors (KEYNOTE426 [ClinicalTrials.gov 
443 number, NCT02853331]). This has culminated in the use of all three agents in some anticancer regimes 
444 eg atezolizumab, bevacizumab, carboplatin and paclitaxel used in combination for the treatment of 
445 non-small cell lung cancer (NSCLC) within IMPower150 (ClinicalTrials.gov number, NCT02366143). 
446 Given the propensity for immune checkpoint inhibitors to interact and display phenotypically typical 
447 hypersensitivity reactions the ability to predict individuals at risk of hypersensitivity or particular drug 
448 combinations which carry an increased risk is increasingly important. It also remains to be seen if there 
449 is a characterizable dose-toxicity relationship or whether there is a temporal relationship to 
450 hypersensitivity. It is known that as monoclonal antibodies, immune checkpoint inhibitors have long 
451 half-lives (6.1-25 days) (124) and receptor occupancy exists for weeks. However it is currently unclear 
452 if there is a dynamic relationship with hypersensitivity and the duration of risk. 
453 Tim-3 is an immune checkpoint receptor that interacts with its ligand galectin 9 to modulate Th1 CD4+ 
454 T-cell responses. The expression of Tim-3 has recently been shown to be significantly reduced on 
455 peripheral blood CD4+ T-cells in the acute phase of drug-induced manculopapular exanthema (125), 
456 a classical Th1-mediated iatrogenic disease. Furthermore, galectin 9 expression and release was 
457 reduced on dendritic cells. These data indicate that the Tim-3 immune checkpoint also contributes to 
458 the maintenance of drug tolerance and the prevention of hypersensitivity reactions. 
459 Contact allergy is a CD8+ T-cell mediated delayed-type hypersensitivity reaction brought about by low 
460 molecular weight haptens. Unlike drug hypersensitivity, where for the most part murine models do 
461 not exist, contact allergy can be reproduced easily in mice through direct application of the hapten to 
462 skin. In recent years, contact allergy has been used to explore how Toll-like receptors, the 
463 inflammasome and endogenous danger signals impact on the hapten specific CD8+ T-cell response 
464 and skin inflammation (126-130). Most recently, Gamradt et al., (131) discovered that intrinsic control 
465 mechanisms such as immune regulatory (PD-1 and TIM-3) signalling determine whether the cytotoxic 































































466 CD8+ T-cells will be reactivated and hence prevent tissue injury. Blocking of immune checkpoints in 
467 vivo lead to severe contact hypersensitivity responses with low hapten doses. 
468 Immune checkpoint blockade has been used in mice to attempt to develop animal models of drug-
469 induced liver injury with a delayed onset (132-135). Treatment of mice with therapeutic doses of 
470 human liver injury inducing compounds such as amodiaquine, isoniazid and nevirapine did not result 
471 in significant tissue damage. However, when the drugs were administered in the presence of PD-1 and 
472 CTLA-4 block, mild, but significant, delayed onset liver injury was observed. Liver injury was associated 
473 with hepatic recruitment of immune cells including CD8+ T-cells, suggesting that they participate in 
474 the pathogenesis. Although this work represents an important step forward – an in vivo model is now 
475 available to begin to study drug-induced delayed-typed liver injury - additional studies are required to 
476 determine why the liver injury does not progress to the serious forms of tissue damage seen in human 
477 patients. 
478 From the above discussion one can begin to visualize how immune checkpoint signalling impacts on 
479 the co-regulatory/co-stimulatory network that determines whether an effector response will ensue 
480 following antigen exposure as well as the strength and duration of the response. As one pathway is 
481 blocked other pathways exert an increased influence in an attempt to maintain tolerance. As we move 
482 forward combined immune checkpoint therapy will become more commonplace. This will result in an 
483 increase in serious autoimmune side effects. However, it is highly likely that drug hypersensitivity 
484 reactions will also become more prevalent.     
485
486 Regulatory T-cells (Tregs)
487 Tregs regulate or suppress other cells in the immune system. They control the immune response to 
488 self and foreign antigens and help prevent autoimmune disease and allergy. Natural Tregs are 
489 identified by expression of the regulatory transcription factor FOXP3. Natural Tregs express CD4+ and 
490 CD25+ (136); however, CD25+ is also expressed on other forms of T-cell including activated T-cells. 
491 Thus, there was a search for additional classification markers. CD127+ has been identified as a marker 
492 that is only expressed at low levels on Tregs and can be used alongside CD4+, CD25+ and FOXP3 to 
493 identify natural Tregs (137, 138). Tregs can also be classified according to the expression of a naïve T-
494 cell marker CD45RA (139). CD45RA+FOXP3lowCD4+ (CTLA-4low, CD25high, CD127low) cells are referred to 
495 as naïve or inducible Tregs. These cells exhibit weak suppressive activity until they differentiate 
496 following antigen-mediated T-cell receptor engagement. They differentiate into effector Tregs 
497 (CD45RA-FOXP3highCD4+) that display a range of additional markers including CTLA-4, CD25+, PD-1, 































































498 TIM-3 and secretory molecules such as IL-10 and TGF-. These cells display a strong inhibitory activity 
499 and increase in number in blood with age. Tregs exert their suppressive function through a range of 
500 pathways ((139-141) Figure 5). These include the inhibition of antigen presenting cells through 
501 expression of immune checkpoint receptors, the release of cytokines such as IL-10 and TGF- that 
502 decrease dendritic cell function and the production of pro-inflammatory cytokines and restriction of 
503 IL-2 for effector T-cells through CD25+ ligation. 
504 A plethora of studies have shown that FOXP3+ Tregs suppress hypersensitivity reactions to chemical 
505 contact allergens in mice by blocking effector CD8+ T-cell responses (142-144). Gomez de Aguero et 
506 al (145) reported that Langerhans cells (cutaneous dendritic cells) are critical in the regulatory process 
507 through inducing the depletion of antigen-responsive T-cells and by activating FOXP3+ Tregs. 
508 Furthermore, in vivo expansion of Treg populations has been shown to induce long-term suppression 
509 of contact hypersensitivity (146). In humans, Cavani et al (147) have reported that CD25+ regulatory 
510 T-cells maintain tolerance to the contact metal allergen nickel in non-hypersensitive individuals. T-
511 cells showed a limited capacity to proliferate in the presence of nickel ex vivo. However, T-cell 
512 activation was strongly increased when Tregs were depleted from the PBMC population. Collectively, 
513 the data generated showed that Tregs blocked the efficient activation of naïve and memory nickel-
514 specific T-cells. It will be interesting to see whether similar pathways (possibly when Tregs are 
515 depleted alongside checkpoint inhibition) are active in drug tolerant patients.
516 In in vitro T-cell priming assays with PBMC from healthy human donors, the depletion of FOXP3+ Tregs 
517 is important to detect CD4+ and CD8+ T-cell responses to drugs and haptenic chemicals (95, 148, 149). 
518 The reintroduction of Tregs to naïve T-cell priming assays block the activation of naïve T-cells by drugs 
519 in a cell concentration-dependent manner (114). Inducible effector Tregs (presumably drug peptide 
520 complex-responsive) are generated in vitro alongside effector CD4+ and CD8+ T-cells during the 
521 priming of naïve T-cells (unpublished data), further emphasizing their importance at regulating drug-
522 specific immune responses. There is a potential for environmental and genetic factors to modulate 
523 the expression and activity of Tregs. For example, polymorphic variants of FOXP3 have been linked to 
524 various forms of autoimmune disease, while exposure to air pollution can methylate the FOXP3 locus, 
525 compromising Treg function (150-153). Thus, Tregs might be important in maintaining an effective 
526 level of tolerance in all drug-exposed patients. 
527 Little is known about the influence of Tregs and Treg dysregulation in the acute phase of a drug 
528 hypersensitivity reaction. In patients with toxic epidermal necrolysis, the most severe form of 
529 blistering skin eruption, Takahashi et al described a functional impairment of Tregs and a reduced 
530 capacity to suppress effector T-cell responses to drugs (154, 155). However, the key mechanisms 































































531 implicit in Treg dysregulation were not defined. Recently, Wang et al. demonstrated that treatment 
532 with a TNF- antagonist reduced skin healing time in patients with severe forms of toxic epidermal 
533 necrolysis (156). Drug treatment decreased TNF- and granulysin levels in blister fluid and significantly 
534 increased Treg proportions in patients during the recovery phase.  In patients with a different form of 
535 severe cutaneous hypersensitivity reaction, DRESS, CD14+ monocytes have been shown to mediate a 
536 gradual shift from a Treg to a Th17 phenotype during the course of the disease (157). In an 
537 independent study, lesional skin of patients with DRESS was found to be rich in FOXP3+ cells and the 
538 increase in Tregs positively correlated with the number of recorded days from the onset of the disease 
539 (158). Similarly, Hanafusa et al, found a switch in the population of dividing cells from CD8+ to FOXP3+ 
540 Tregs in drug-treated PBMC from a patient with DRESS (159). Collectively, these data indicate that the 
541 Tregs are being activated and recruited to inflamed skin to attempt to control the strength and 
542 duration of the drug-specific effector T-cell response. Thus, it is important to develop strategies to 
543 understand the role Tregs play in determining the outcome of drug exposure in patients. 
544 Recently, breaking tolerance through depletion of murine CD4+ T-cells was found to result in the 
545 development of abacavir hypersensitivity in a HLA-B*57:01 transgenic model (160). Abacavir exposure 
546 per se induced a CD8+ T-cell response; however, the mice maintained an anergic disease state. An 
547 adverse reaction in skin was only detected when CD4+ T-cells, which included Tregs, were depleted.  
548 The epidermis became heavily infiltrated with CD8+ T-cells and skin showed typical signs of tissue 
549 injury. The authors demonstrated through a series of detailed experiments that CD4+ T-cell depletion 
550 resulted in optimal dendritic cell co-stimulation and a break in regulation, predisposing the mice to 
551 tissue injury.         
552
553 Cytokines
554 During T-cell priming, naïve CD4+ T-cells differentiate into one of several linages, including Th1, Th2, 
555 Th17, Th22 and induced Tregs. Each T-cell population is characterized by the cytokines they secrete 
556 when activated. Importantly, the cytokine microenvironment during T-cell receptor triggering controls 
557 T-cell differentiation (Figure 6). The impact of the cytokine microenvironment on T-cell polarization 
558 can be demonstrated experimentally by culturing purified human T-cells with relevant cytokine 
559 cocktails (Th1, IL-12 & anti-IL-4; Th2, IL-4, anti-IL-12 & anti-IFN-; Th17, IL-1, IL-6, IL-23 & TGF-; Th22, 
560 TNF- & IL-6) for 7 days prior to non-specific mitogen stimulation. Activated T-cells secrete the 
561 polarized cytokines illustrated in Figure 6. The activation of CD8+ T-cells is also influenced by cytokines. 
562 In the absence of specific cytokine signals, CD8+ T-cells become anergic and unresponsive to antigen 































































563 stimulation. The dominant cytokines that promote CD8+ T-cell activation are IL-12 and IFN-/ (161, 
564 162). 
565 There are many examples of disease induced cytokine imbalance (163-165) and this could have a 
566 major impact on the outcome of drug exposure. Diseases such as HIV and cystic fibrosis predispose 
567 individuals to drug hypersensitivity reactions. In patients with HIV the incidence of sulfonamide 
568 hypersensitivity is 10 times higher when compared with non-HIV infected patients (166). Cytokine 
569 imbalances such as Th1/Th2 switching are common features in patients with HIV as the disease 
570 progresses (167), but to date the impact of these changes on susceptibility to drug hypersensitivity 
571 has not been studied. Similarly, when patients with cystic fibrosis were compared to the general 
572 population, antibiotic reactions were found to be up to three times more common (100). The cystic 
573 fibrosis lung represents an area of chronic inflammation with high neutrophil numbers alongside 
574 elevated levels of cytokines such as IL-8, IL-1, IL-6, IL-17 and TNF- (168-170). Obviously, this will 
575 have a colossal impact on the outcome of T-cell receptor triggering through altered antigen 
576 presentation as well as differential polarization of the effector T-cell response. However, to date, it 
577 has not been possible to establish models/systems to explore this relationship directly.        
578         
579 Conclusions      
580 It is becoming increasingly apparent that multiple tolerance pathways determine the outcome of 
581 antigen exposure through regulation of (i) naïve T-cell activation and (ii) the strength and duration of 
582 the effector T-cell response. Through the studies discussed herein we are beginning to understand 
583 that similar pathways are active in patients at the time of drug exposure and that immune regulation 
584 networks contribute towards the outcome of drug exposure: health benefit or a hypersensitivity 
585 reaction. Work is required to define how the distinct pathways contribute towards individual 
586 susceptibility. Such studies are urgent given the plethora of immune modulatory drugs that are in 
587 development, which once approved will be administered alongside traditional low molecular weight 
588 drugs. It will also be important to determine whether low molecular weight drugs modulate tolerance 
589 pathways in patients and whether this contributes to the successful desensitization of certain 
590 hypersensitive patients.            
































































592 Table 1. HLA class I allele-associated drug hypersensitivity reactions with known drug HLA binding 
593 interactions for T-cell activation 




Abacavir hypersensitivity HLA-B*57:01 (7) Direct non-covalent binding 
(9, 171)
Yes, aldehyde (172)











Direct labile drug & 
metabolite binding (173, 
174)
Yes, multiple metabolites 
(175, 176)
Carbmazepine skin reactions HLA-A*31:01 
(86)
Direct labile drug & 
metabolite binding (173, 
174)
Yes, multiple metabolites 
(175, 176)
Dapsone drug reaction with 




Direct labile & metabolite 
covalent binding (17, 177)
Yes, nitroso metabolite 
(178, 179)
Flucloxacillin liver injury HLA-B*57:01 
(83)







Direct labile & metabolite 
covalent binding (4, 71, 72)
Yes, nitroso metabolite 
(180)
Co-amoxiclav liver injury HLA-A*02:01 
(87)
Direct covalent binding  (42) Not applicable (48)
Minocycline liver injury HLA-B*35:02 
(89)
Unknown Yes, quinone iminium ion 
(181)
Terbinafine liver injury HLA-A*33:01 
(90)
Unknown Yes, aldehyde metabolite 
(182)
Ticlopidine liver injury HLA-A*33:03 
(183)
Direct labile binding (184) Yes, sulfenic acid (185)
Vancomycin drug reaction 






595 aalternative pathways feasible for all compounds, but to date have not been studied
596 bformation of a metabolite does not indicate that they are involved in the reaction
































































598 Figure 1. The drug hypersensitivity susceptibility conundrum proposes that if we assume exposure to 
599 a drug and the availability of HLA proteins and T-cell receptors for drug peptide complexes are kept as 
























































































606 Figure 2. The influence of drug- and patient-specific factors on drug immunogenicity and 
607 hypersensitivity.  Drug exposure and the availability of HLA proteins and T-cell receptors for drug 
608 binding are essential for immunogenicity. However, these factors either together or in isolation do not 
609 predict whether a patient will develop hypersensitivity. This is because immune regulatory pathways 
610 control whether a pathogenic immune response will develop. These pathways may influence p-I and 
611 hapten responses to different extents although this is yet to be proven even in the case of abacavir. 
612 The bottom component of the figure highlights the nature of the drug immune receptor binding 
613 interaction, the requirement for antigen processing and the derivative that T-cell receptors interact 

























Non-covalent to HLA, 
peptide or TCR 
























































































619 Figure 3. The balance between co-stimulatory and co-inhibitory pathways are the key determinant of 
620 whether drug exposure will result in hypersensitivity. This balance is influenced by genetic, disease 
621 and environmental factors. Thus, the balance will differ across individuals and within the same 
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624 Figure 4. Co-inhibitory receptors regulate the strength of the drug-specific T-cell response and hence 














• Enhanced cytokine release
• Enhanced cytotoxicity































































628 Figure 5. Tregs regulate the strength of antigen-specific effector T-cell responses and hence may alter 
629 the balance between tolerance and hypersensitivity following drug exposure.
630
Tregs:
Tregs produced in the thymus 
are termed natural
Treg formed by differentiation 
of naïve T cells outside the 





• Apoptosis of effector cells
• Modulation of DC function






• Decrease in T-cell proliferation
• Decrease in MHC and co-stimulatory molecules
• Decrease in APC function
• Decrease in inflammatory cytokines
Cell-cell contact 
(eg. CTLA-4)




































































631 Figure 6. Cytokine control of T-cell differentiation.
632
633
Th1 Th2 Th17 Th22 Treg





































































































636 Text box 1. Major Milestone Discoveries 
637  Drug, drug metabolite and drug-modified peptide HLA binding activates T-cells in 
638 patients with hypersensitivity
639  Development of assays with PBMC from healthy human donors to study naïve drug 
640 peptide complex T-cell priming ex vivo
641  Individual HLA alleles are important determinants of disease susceptibility
642  Characterisation of HLA-allele-restricted drug-specific T-cell responses in patients with 
643 drug hypersensitivity.
644  Co-inhibitory receptors impact on the ability of drug peptide complexes to activate naïve 
645 T-cells
646  Discovery of an increased incidence of drug hypersensitivity reactions in patients 
647 receiving immune checkpoint inhibitor therapy  
648
649 Text Box 2. Future Research Perspectives
650 Genome-wide association studies and functional assessment of patient T-cells have taught us that 
651 drug peptide complexes interact selectively and specificity with HLA proteins to bring about 
652 hypersensitivity reactions. It is now important to define, through detailed structural analysis, the way 
653 in which drug peptide complexes bind to HLA proteins. The nature of the interaction will differ drug-
654 to-drug. It is also important to determine the contribution different forms of drug peptide complex 
655 play in the disease pathogenesis as we know that parent drug, metabolite and drug-modified peptide-
656 responsive T-cells circulate in patients’ blood and tissues.  
657 Of particular importance, is identification of the parameters that that influence susceptibility in 
658 patients expressing known HLA risk alleles. Ongoing studies seem to suggest that drugs stimulate a 
659 very restricted repertoire of T-cells in patients with Stevens Johnson syndrome. Might this be the case 
660 in other forms of drug hypersensitivity? The balance between co-stimulatory and co-inhibitory 
661 signalling during drug peptide complex-specific T-cell priming is also an important determinant of 
662 susceptibility. Future research must focus on patients at the earliest stages of a reaction to delineate 
663 the contribution individual pathways (e.g, receptor signalling, Tregs, cytokines) in play in 
664 determination of the outcome of drug exposure. In this respect, important lessons will be learned 
665 from patients receiving immune checkpoint inhibitor therapy for cancer treatment.    
666
667
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19 Abstract: Delayed-type, T-cell mediated, drug hypersensitivity reactions are a serious unwanted 
20 manifestation of drug exposure that develops in a small percentage of the human population. Drugs 
21 and drug metabolites are known to interact directly and indirectly (through irreversible protein 
22 binding and processing to the derived adducts) with HLA proteins that present the drug-peptide 
23 complex to T-cells. Multiple forms of drug hypersensitivity are strongly linked to expression of a single 
24 HLA allele and there is increasing evidence that drugs and peptides interact selectively with the protein 
25 encoded by the HLA allele. Despite this, many individuals expressing HLA risk alleles do not develop 
26 hypersensitivity when exposed to culprit drugs suggesting a non-linear, multifactorial relationship in 
27 which HLA risk alleles are one factor. This has prompted a search for additional susceptibility factors. 
28 Herein, we argue that immune regulatory pathways are one key determinant of susceptibility. As 
29 expression and activity of these pathways is influenced by disease, environmental and patient factors, 
30 it is currently impossible to predict whether drug exposure will result in a health benefit, 
31 hypersensitivity or both. Thus, a concerted effort is required to investigate how immune dysregulation 
32 influences susceptibility towards drug hypersensitivity. 
33
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36 Drug hypersensitivity refers to objectively reproducible symptoms or signs initiated by exposure to a 
37 drug at a dose normally tolerated by non-hypersensitive persons (1). Hypersensitivity is also 
38 commonly referred to as a form of off-target toxicity, which means that the development of tissue 
39 injury is not predictable from known pharmacology of the drug and there is no simple association 
40 between the dose of the drug administrated and the development of clinical signs and symptoms. 
41 Delayed-type reactions vary in severity and can target individual organs such as liver and skin in 
42 isolation or as part of a generalized hypersensitivity syndrome. Common to the cellular 
43 pathophysiology of drug hypersensitivity is the presence of drug-specific T-lymphocytes in blood and 
44 inflamed tissue (2-4). In fact, cutaneous hypersensitivity reactions (maculopapular, pustular, and 
45 bullous) are classified according the effector molecules secreted by T-cells when activated with drugs 
46 (5, 6).
47 In 2002, Mallal et al. reported a strong association between the presence of HLA-B*57:01, HLA-DR7, 
48 and HLA-DQ3 and hypersensitivity to the HIV-1 reverse-transcriptase inhibitor abacavir (7). 
49 Subsequent studies demonstrated that (i) all skin test confirmed cases of abacavir hypersensitivity 
50 carry HLA-B*57:01 (8), (ii) abacavir interacts selectively with high affinity within the HLA-B57:01 
51 peptide binding cleft through non-covalent interactions (9-11), and (iii) abacavir only activates CD8+ 
52 T-cells (12-14). It is important to note that the abacavir association differs from all other forms of HLA-
53 linked hypersensitivity reaction. For example, drug-responsive CD4+ and CD8+ T-cells are observed in 
54 patients hypersensitive to drugs such as carbamazepine, dapsone, flucloxacillin who express the 
55 relevant HLA class I risk alleles, B*15:02, B*13:01 and B*57:01, respectively (15-17). These data 
56 indicate that although there is a preference for drug (parent drug, metabolite) peptide complex HLA 
57 T-cell receptor binding in patients, binding interactions are generally heterogeneous and this 
58 contributes to the complete adaptive drug-specific T-cell response. Throughout this manuscript we 
59 discuss the different forms of drug HLA interaction in detail highlighting similarities and differences in 
60 pathways that lead to T-cell activation. However, we subsequently use the general term “drug peptide 
61 complex” where appropriate to refer to any drug-derived structure that interacts with HLA proteins 
62 and T-cell receptors to trigger T-cell activation. This is because the formation of an HLA, drug, peptide 
63 and T-cell receptor complex is necessary for all pathways of T-cell activation. It is simply the nature of 
64 the complex and form of binding interaction that differs. As the number of associations between drug 
65 hypersensitivity and HLA allele expression increases (18-20), it is important to consider the additional 
66 patient factors that confer susceptibility. This is of particular importance because not all patients 
67 expressing a risk HLA are susceptible, while many patients lacking known risk alleles go on to develop 
68 hypersensitivity when exposed to culprit drugs. 































































69 Three factors are critical for the activation of T-cells with drugs; exposure to a drug peptide complex, 
70 the availability of a T-cell repertoire for a drug peptide complex and a protein encoded by HLA alleles 
71 for drug peptide complex binding. The argument is presented that although each factor detailed above 
72 is critical for drug immunogenicity; separately or together, they cannot be used to predict patient 
73 outcome following drug exposure. We hypothesize that when each factor is present, active immune 
74 regulatory pathways (co-inhibitory receptors, Tregs, cytokines) are key determinants of whether drug 
75 exposure will result in hypersensitivity. Since expression and activity of these regulatory pathways are 
76 altered by disease, the genetic make-up of the host and environmental factors, it is currently 
77 impossible to predict whether drug exposure will result in a health benefit, hypersensitivity or both 
78 (Figure 1).  
79
80 Different manifestations of drug hypersensitivity
81 Drug-induced cutaneous reactions: Although skin rashes are common forms of drug hypersensitivity, 
82 serious and life-threatening reactions develop much less frequently. Examples of serious cutaneous 
83 hypersensitivity reactions include Stevens-Johnson syndrome, toxic epidermal necrolysis and drug 
84 reaction with eosinophilia and systemic symptoms (DRESS). Although less serious than the conditions 
85 listed above, acute generalised exanthematous pustulosis and maculopapular exanthema are also 
86 important adverse drug reactions. A broad spectrum of different drugs may cause cutaneous reactions 
87 including the sulfonamides, allopurinol, carbamazepine, dapsone and many of the penicillins (21-24) . 
88 Although there is some degree of pathophysiological overlap, there are some clinically defining 
89 features for each type of severe cutaneous adverse drug reaction and these are briefly discussed 
90 below. 
91 The most common skin manifestation is maculopapular exanthema which accounts for approximately 
92 95% of all cutaneous reactions (25). These are reported as eruptions starting on the trunk and upper 
93 extremities and progressively become more prevalent. These reactions are not life-threatening and 
94 almost always often subside even with when the continued dosing with the culprit drug has been 
95 withdrawn (26). Antibiotics and a number of tuberculosis medications such as rifampicin, isoniazid, 
96 pyrazinamide and ethambutol are common causes of maculopapular exanthema (27).
97 Acute generalised exanthematous pustulosis represents a more severe, usually drug-related skin 
98 reaction characterised by the presence of sterile pustules on an erythematous surface along with fever 
99 and neutropenia neutrophilia in a patient. Furthermore, the involvement of activated neutrophils 
100 along with excessive production of cytokines IL-8 and IL-17 is characteristic of acute generalised 































































101 exanthematous pustulosis, stimulating the recruitment to tissues and the induction of innate immune 
102 responses (28).
103 DRESS is a severe skin reaction with an incidence of between 1:1000 and 1:10000 in patients exposed 
104 to culprit drugs such as anticonvulsants, antimicrobials and antivirals (29). The reaction is 
105 characterised by skin eruptions, fever as well as symptoms in other organs, such as hepatitis, nephritis 
106 and thyroiditis (30). DRESS has been shown to be regulated by the cellular actions of eosinophils 
107 mediated via the secretion of IL-5 from drug-specific T-cells (31). Furthermore DRESS is often 
108 associated with reactivation of several viruses, including HHV-6, CMV and EBV (32) (33). 
109 Stevens-Johnson syndrome and toxic epidermal necrolysis define increasing degrees of severity of the 
110 same skin disease and are often grouped together. The disease involves the mucosal membranes 
111 including the eyes, mouth and genitals (30). The level of skin detachment can be used to categorise 
112 the severity of the reaction. The clinical definition of Stevens-Johnson syndrome is when the 
113 detachment of epidermal sheets remains on small areas and occurs on less than 10% of the body 
114 surface area. Stevens-Johnson syndrome/toxic epidermal necrolysis overlap is when this value is 
115 between 10-30% and toxic epidermal necrolysis patients experience large sheets of skin detachment 
116 exceeding 30% of the body surface area (34).
117 Drug-induced liver injury: The liver is the largest organ in humans; it is the major organ responsible for 
118 the metabolism and detoxification of drugs. Hepatocytes (parenchymal cells) make up about 85% of 
119 the liver while non-parenchymal cells, including liver sinusoidal endothelial cells, hepatic stellate cells, 
120 Kupffer cells and biliary epithelial cells make up the remaining 15% and play important roles in 
121 maintaining the homeostasis of the liver. Drug-induced liver injury is a major reason for drug attrition 
122 and withdrawal of drugs in clinical trials or drugs already licenced for clinical use (35). Worldwide, the 
123 estimated annual incidence rate of drug-induced liver injury is 0.02% (36, 37). Hoofnagle and 
124 Björnsson have recently classified drug-induced liver injury into three categories (direct, 
125 indirect and idiosyncratic) according to frequency, predictability and reaction mechanisms 
126 (38). Direct liver injury is common and occurs rapidly when drugs are given at high doses (e.g., 
127 paracetamol). Indirect liver injury has an intermediate frequency, is partially predictable and 
128 occurs as an indirect action of the drug on liver or the immune system (e.g., monoclonal 
129 antibodies). Finally, idiosyncratic liver injury occurs in only a small number of individuals, is 
130 not predictable and involves activation of the patients adaptive immune system.  and tThe 
131 mean onset of idiosyncratic liver injury tissue damage with certain drugs exceeds 100 days (39). 
132 Amoxicillin, clavulanic acid, NSAIDS, flucloxacillin, lapatinib, lumiracoxib, ximelagatran among other 
133 drugs have been implicated with various degrees of unpredictable/idiosyncratic liver injury. Several 































































134 forms of drug-induced liver injury are strongly associated with expression of specific HLA alleles (40). 
135 This, alongside the delayed onset of clinical symptoms, is indicative of pathogenesis involving drug-
136 specific T-cellsthe adaptive immune system. Recent studies have identified and characterized drug-
137 responsive CD4+ and CD8+ T-cells from the peripheral blood of patients with tuberculosis medicine-, 
138 co-amoxiclav- and flucloxacillin-induced liver injury (41-43). Furthermore, T-cells infiltrate have been 
139 shown to infiltrate liver and kill hepatocytes through the release of cytolytic molecules (44, 45).    
140 Drug-induced hematologic disorders: Agranulocytosis, aplastic anaemia, megaloblastic anaemia and 
141 thrombocytopenia are major forms of drug-induced hematologic disorders. Drugs can directly target 
142 progenitor cells in the bone marrow or peripheral blood cells in the systemic circulation (46, 47). These 
143 adverse drug reactions are rare but can result in significant mortality. Various classes of drugs have 
144 been linked with drug-induced hematologic disorders. Examples include antibacterial, anti-
145 inflammatory, antithyroid, antimalarial, antiepileptic, antidepressant and antipsychotic drugs. Similar 
146 to skin and liver reactions, drug-induced hematologic disorders can unpredictable. Genome wide 
147 association studies have linked some variants of HLA-DQB1 and HLA-B allele to clozapine-induced 
148 agranulocytosis providing evidence for an immune pathogenesis. There is also evidence to suggest 
149 that drugs which cause hematologic disord rs can activate (i) inflammasomes, (ii) B-cells to produce 
150 anti-drug antibodies and (iii) cytotoxic T-cells ((48-50) unpublished data).  
151
152 Does drug exposure impact on susceptibility to hypersensitivity?
153 For this discussion, we assume that the initiating event for T-cell activation is either a drug or drug 
154 metabolite binding directly to the HLA T-cell receptor complex (through either covalent or non-
155 covalent binding) or a drug or drug metabolite binding indirectly to non-HLA proteins (through 
156 covalent binding; the HLA binding epitope being a peptide derived from the modified protein, which 
157 may or may not contain the drug moiety).   
158 In consideration of the latter first, most research has been conducted on biological samples from 
159 patients with -lactam hypersensitivity. For adduct formation, the β-lactam ring is targeted by lysine 
160 residues. Nucleophilic attack leads to ring opening and binding of the penicilloyl group to the lysine 
161 residue (51). -lactam antibiotics modify serum proteins such as serum albumin and multiple 
162 intracellular proteins (52-56). Protein adducts are transported to antigen presenting cells via exosomal 
163 transport (55, 57) and -lactam-modified protein and peptide adducts have been shown to activate 
164 patient T-cells (15, 58-62). Importantly, these adducts are formed in all drug exposed patients (53, 63-
165 65), those who develop skin and liver reactions as well as those that safely tolerate the drug. 
166 Moreover, through the synthesis of -lactam-modified peptides as standards for mass spectrometric 































































167 analysis, Meng et al (63) were able to quantify and compare the level of drug albumin binding in 
168 hypersensitive and tolerant patients. No clear differences in the level of -lactam antibiotic lysine 
169 modification was detected between the two patient groups, and importantly, the level of modification 
170 in all patients exceeded the threshold required for activation of -lactam antibiotic-responsive T-cells. 
171 Obviously, additional studies are required to explore whether hapten thresholds are exceeded in 
172 patients receiving others -lactam antibiotics and hapteneic drug metabolites. However, currently 
173 available data suggests that although the formation of drug protein adducts may be an important, if 
174 not critical factor for drug immunogenicity, the level of therapeutic drug exposure does not seem to 
175 be a key determinant of patient outcome. One way to confirm this would be a detailed comparison of 
176 the incidence of hypersensitivity reactions in patients receiving higher and lower -lactam doses or 
177 longer and shorter treatment courses, as long as this doesn’t impact on clinical care.   
178 An assortment of drug structures activate T-cells through a direct non-covalent interaction with HLA 
179 and/or specific T-cell receptors. The p-I concept has been coined to explain this phenomenon and 
180 differentiate this pathway of T-cell activation from the hapten concept. A number of pieces of 
181 experimental evidence support this direct binding concept: first, the addition of parent drug to human 
182 immune cell culture systems that express low levels of drug metabolizing enzymes leads to a T-cell 
183 response characterized by proliferation and cytokine and cytolytic molecule release (66-68); second, 
184 inhibition of protein processing within antigen presenting cells, which blocks T-cell responses to 
185 protein antigens has no effect on the activation of T-c lls with drugs (69, 70); and third, the kinetics of 
186 T-cell activation with drugs is rapid, within minutes (14, 71), which is in stark contrast to classical 
187 antigen presentation pathways that require several hours. Many drugs have been shown to activate 
188 T-cells from hypersensitive patients via this pathway, including sulfamethoxazole (70), carbamazepine 
189 (72, 73) and allopurinol (71). However, with the exception of abacavir, the nature of the drug peptide 
190 HLA T-cell receptor interaction is yet to be defined. The selective interaction of abacavir with HLA-
191 B*57:01 alters the spatial arrangement of molecules within the peptide binding groove. This results in 
192 the display of novel “altered” HLA-B*57:01 peptide sequences that seemingly go on to stimulate T-
193 cells that bring about abacavir hypersensitivity (9-11, 74). Adam et al. (74) demonstrated that 
194 abacavir-responsive T-cells stemming from naïve and memory compartments are detectable in 100% 
195 of donors expressing HLA-B*57:01. This led the authors to suggest that abacavir T-cell reactivity by-
196 passes normal co-stimulatory/regulatory requirements. However, we draw readers attention to the 
197 fact that it has not been possible to explain why only half of HLA-B*57:01+ donors (who all possess 
198 abacavir-responsive T-cells) exposed to abacavir develop hypersensitivity. It should also be noted that 
199 p-I- and hapten-responsive T-cells are not always detected in isolation. For the -lactam antibiotics 































































200 (60, 75) and sulfonamides/sulfones (17, 76, 77), the only drug exemplars studied to date, drug p-i- and 
201 hapten-responsive T-cells are found together. 
202 Drugs administered at a high mass dose more frequently cause hypersensitivity reactions, when 
203 compared with drugs administered at lower doses (78). However, in humans, individual drugs tend to 
204 be administered at similar doses using dosing regimens directed to achieve drug concentrations within 
205 a therapeutic window for a sustained duration of time. Humans are therefore exposed to similar 
206 plasma concentrations of the parent drug. A handful of studies describe associations between 
207 metabolism (increased production of metabolite or increased exposure to parent drug) and the 
208 incidence of drug hypersensitivity reactions (79). For example, CYP2C9*3, which decreases phenytoin 
209 clearance is associated with an increased occurrence of anticonvulsant hypersensitivity (80, 81). 
210 Similarly, impaired renal function and increased plasma levels of oxypurinol (the metabolite that 
211 drives T-cell responses in hypersensitive patients (82)) correlate with the poor prognosis of 
212 allopurinol-induced severe cutaneous hypersensitivity reactions (83). However, these findings seem 
213 to be an exception, rather than a rule, as few other studies have reported associations between drug 
214 disposition and hypersensitivity. 
215 It is clear that a threshold level of drug exposure must be surpassed for the activation of T-cells. In 
216 agreement with this, most drugs that have been withdrawn from the market or have received black 
217 box warnings due to liver injury are administered at daily doses greater than 50 mg per day (84, 85).  
218 However, it is difficult to argue susceptibility to drug hypersensitivity is solely dependent upon plasma 
219 drug concentrations or the drug concentration at the site of T-cell activation. The vast majority of 
220 patients tolerate therapeutics drug concentrations with little or no adverse effects. Thus, for the 
221 purpose of this review we argue that everyone taking medicinal drugs may be exposed to therapeutic 
222 concentrations that are capable of forming HLA drug peptide complexes and delivering them to T-
223 cells. 
224
225 Does the display of drug peptide complexes by human leukocyte antigen proteins impact on 
226 susceptibility to hypersensitivity?
227 A plethora of studies, starting with abacavir discussed above, have identified astonishingly strong 
228 associations between HLA class I alleles and susceptibility to drug hypersensitivity reactions, which 
229 implies a direct effect of the gene product on the disease (86, 87) (Table 1 shows several HLA class I 
230 allele-associated drug hypersensitivity reactions with known drug peptide complex HLA binding 
231 interactions for T-cell activation). This suggests that mechanistically, restriction of the fit of the drug 
232 and peptide into HLA proteins is important for T-cell activation. HLA-B*57:01, which is associated with 































































233 abacavir hypersensitivity, has a positive predictive value of 55 % and a negative predictive value of 
234 100 % (8). This means that only individuals carrying the allele are at risk and 1 out of 2 carriers develop 
235 hypersensitivity following abacavir exposure. Genetic screening prior to abacavir use is routine 
236 practice and eradicates the appearance of hypersensitivity. Other forms of HLA class I associated 
237 hypersensitivity (e.g., flucloxacillin [HLA-B*57:01] (88), allopurinol [HLA-B*58:01] (21), carbamazepine 
238 [HLA-B*15:02] (89) and dapsone [HLA-B*13:01] (90)) display similar negative predictive values (99-
239 100%) in specific patient groups; however, the positive predictive value is much lower. This suggests 
240 that the HLA allele is essential for drug peptide complex display, but other factors determine whether 
241 drug exposure results in a T-cell response and hypersensitivity. In a final group of HLA class I associated 
242 reactions (e.g., carbamazepine [HLA-A*31:01] (91), co-amoxiclav [HLA-A*02:01] (92), 
243 sulfamethoxazole [HLA-B*38:02] (93), minocycline [HLA-B*35:02] (94) and terbinafine [HLA-A*33:01] 
244 (95)), the carrier frequency in hypersensitive patients is 50% or lower. Thus, in these reactions, the 
245 drug-peptide complex is displayed by a number of different HLA proteins to activate T-cells. Additional 
246 forms of drug hypersensitivity are (i) linked to expression of HLA class II allele(s) or (ii) not known to 
247 be associated with expression of a specific HLA allele despite the fact that drug-specific CD4+ and CD8+ 
248 T-cells are detectable. Importantly, it has not been possible to show that selective drug peptide 
249 complex binding to HLA class II proteins, identified as risk factors, leads to the activation of CD4+ T-
250 cells (authors unpublished data). 
251 Drug-peptide complex HLA protein binding is without doubt critical for the development of drug 
252 immunogenicity; however, from the above discussion it is clear that for most HLA allele associated 
253 reactions, expression of the HLA protein alone does not determine whether drug exposure will result 
254 in hypersensitivity.
255          
256 Does expression of specific T-cell receptors impact on susceptibility to hypersensitivity?
257 Advances in high-throughput sequencing technologies has enabled the detailed analysis of global T-
258 cell repertoires in patients with and without immunological diseases. Glanville et al. (96) recently 
259 defined the minimal requirements for T-cell receptor specificity through an analysis of T-cell receptor 
260 sequences using a panel of HLA binding peptides. Focussing on 5711 T-cell receptor V chain 
261 sequences from CD4+ T-cells derived from 22 donors with mycobacterium tuberculosis, they identified 
262 141 T-cell receptor specificity groups including 16 groups containing T-cell receptors from at least 3-4 
263 individuals with shared alleles. The T-cell receptors shared HLA alleles from different donors for shared 
264 peptide presentation. These data indicate that a diverse array T-cell receptor sequences are available 
265 in any individual that interact with peptide ligands from a single protein antigen. Similar technologies 































































266 should be applied to the study of drug hypersensitivity to explore whether shared drug peptide 
267 complex specificity clusters are present across different donors and whether this correlates with 
268 disease. 
269 Our knowledge of how T-cell receptor sequences impact on drug hypersensitivity is in its infancy. 
270 Through global expression level analysis and assessment of the third complementary-determining 
271 region length distribution of the T-cell receptor profile in patients with carbamazepine-induced 
272 Stevens-Johnson syndrome, Ko et al. (97) identified VB-11-ISGSY as a dominant clonotype shared 
273 amongst different hypersensitive, but not drug-tolerant, donors. Furthermore, carbamazepine-
274 specific cytotoxic T-cells could be primed from PBMC of healthy human donors that were carriers of 
275 both HLA-B*15:02 and VB-11-IsGSY. More recently, the same group working on the same patient 
276 cohort reported the detection of a public T-cell receptor composed of paired TCRα CDR3 “VFDNTDKLI” 
277 and TCRβ CDR3 “ASSLAGELF” clonotypes and that similar receptor clusters are found in the blister 
278 fluid cells and peripheral blood (98). These data suggest that the correct combination of HLA, drug 
279 peptide complex and T-cell receptor may be important drivers for carbamazepine-induced Stevens-
280 Johnson syndrome. Unpublished data analysing blister fluid from a different cohort of patients with 
281 Stevens Johnson syndrome after administration of multiple drugs also show an enrichment of T-cells 
282 that display a selective repertoire of T-cell receptor sequences at the most early phase of the adverse 
283 event (Vocanson, personal communication). However, the T-cell receptor identified differs across 
284 patients, even those exposed to the same culprit drug. Moreover, a dominant clonotype was not 
285 detected in all patients. 
286 The proposal that susceptibility to drug hypersensitivity r lates to expression of a single T-cell 
287 clonotype contrasts with published literature showing the polyclonal expansion of T-cells by certain 
288 drugs. Abacavir, which interacts non-covalently with HLA-B*57:01, activates T-cells in 100% of human 
289 donors that carry the risk allele (even though only half develop hypersensitivity when exposed to 
290 abacavir) (99). Analysis of T-cell receptors expressed on abacavir-responsive T-cells did not reveal 
291 skewed patterns (9). This is consistent with abacavir activating an array of different T-cell receptors. 
292 Similarly, nitroso sulfamethoxazole, a cysteine-reactive metabolite of sulfamethoxazole has been 
293 shown to prime naïve CD4+ and CD8+ T-cells from 59/60 healthy human donors (100, 101). 
294 Spectratyping revealed that nitroso-sulfamethoxazole-specific T-cell responses were controlled by 
295 public T-cell receptors present in all individuals alongside private T-cell repertoires specific to each 
296 individual (102). Finally, elegant studies by Azoury et al. (103, 104) utilized immunodominant -
297 lactam-modified peptides derived from albumin to calculate the frequency of naïve CD4+ T-cells that 
298 recognize the drug peptide complex. The haptenated peptides were recognized by naïve T-cells from 
299 13/14 human donors. 































































300 These data, although utilizing a limited number of drugs, cover three forms of drug HLA binding 
301 derivative  (parent drug, drug metabolite and haptenated peptide) and show that PBMC from each 
302 and every one of us contain naïve T-cells capable of recognizing and responding to drugs. Although 
303 certain HLA drug peptide complexes may associate preferentially with specific T-cell receptors and this 
304 may impact on the development of hypersensitivity: as has been described with HLA-B*15:02 and 
305 patients with carbamazepine-induced Stevens Johnson syndrome. It needs to be emphasized that the 
306 Caucasian population very rarely express HLA-B*15:02; they do however still develop carbamazepine 
307 hypersensitivity. The only explanation for this is that carbamazepine interacts with multiple HLA 
308 proteins and T-cell receptors to bring about hypersensitivity reactions.    
309
310 To summarize the discussion thus far, most, if not all, drug-treated patients have a T-cell repertoire 
311 for drug peptide complexes and are exposed to drugs in sufficient quantities to activate the T-cells. 
312 Although expression of a specific HLA protein is important, for many forms of hypersensitivity, HLA 
313 risk allele expression per se does not predict the outcome of drug exposure. Therefore, for the 
314 remainder of this article we focus on the hypothesis that immune regulatory pathways are key 
315 determinants of whether drug exposure in genetically predisposed individuals will result in 
316 hypersensitivity. Figure 2 illustrates that drug exposure, expression of HLA alleles and T-cell receptors 
317 are all important determinants of immunogenicity, whereas regulatory pathways are determinants of 
318 hypersensitivity. The pathways of drug-specific T-cell activation are also depicted with reference to 
319 the possible different requirements for immune regulation. 
320 While immune cells survey the tissue microenvironment for drug-derived signals, a key task is to 
321 maintain tissue homeostasis. The outcome of immune surveillance may be unresponsiveness (the 
322 immune system does not detect the drug-derived signal), a conventional effector response (leading 
323 to hypersensitivity with a drug-derived signal) or tolerance (a state of immunological 
324 unresponsiveness to the drug-derived signal). Tolerance can be natural or induced and these terms 
325 are discussed in more detail below with reference to regulatory T-cells. In the context of drug 
326 hypersensitivity it is important to consider variation in natural tolerance and whether drug treatment 
327 actively induces or alters toleragenic pathways and indeed the potential for certain drug peptide 
328 complexes to bypass natural tolerance.  The way the immune system does regulates immune 
329 responses, and is able to adapt to change, is through the expression of an array of cell surface co-
330 stimulatory and co-inhibitory signalling receptors (Figure 3). Co-stimulatory receptors collect 
331 information from stressed or damaged cells and tissue and determine whether an effector response 
332 should be directed towards an antigen. The co-inhibitory receptors act alongside regulatory T-cells 































































333 (Tregs) and stimulatory and inhibitory cytokines (e.g., IL-10, TGF-) to preserve the regulatory 
334 environment to prevent unwanted immune responses against self and non-damaging agents and to 
335 prevent excessive responses to antigens when a T-cell response has been initiated. Factors that 
336 influence the balance between co-stimulatory and co-inhibitory signalling include the genetics of the 
337 host, disease and environmental factors. 
338 It is possible that each and every one of us may develop a hypersensitivity reaction following drug 
339 treatment if the balance between co-stimulation and co-inhibition is skewed at the time of exposure. 
340 This represents a frightening concept for Pharma and healthcare professionals, since the factors that 
341 control this balance are difficult to predict and will vary across individuals and within an individual 
342 when they are exposed to different immunomodulatory environments (e.g., infections or damaging 
343 agents). For this reason, although it might be possible to work towards a framework to predict the 
344 intrinsic immunogenicity of a drug, prediction of the number of individuals that will ultimately develop 
345 a clinical drug hypersensitivity reaction is very difficult.            
346           
347 Clinical evidence to exclude drug exposure, the availability of a T-cell repertoire or a single genetic 
348 factor as key determinants that impact on susceptibility to drug hypersensitivity 
349 We have worked together with respiratory physicians to understand the chemical and cellular basis 
350 of -lactam hypersensitivity in patients with cystic fibrosis. This patient population is an important 
351 study group as they have been monitored closely throughout childhood and adult life and as such they 
352 have almost complete drug histories as well as detailed records of the nature and timeframe of 
353 hypersensitivity reactions that occur more frequently when compared to the general population (105-
354 107). Piperacillin is a commonly used -lactam antibiotic for the treatment of recurrent respiratory 
355 infections. Patients receive repeated courses of the drug at the same dose (12g/day; iv injection) and 
356 duration (14 days). If one assumes that a patient receives 3 treatment courses a year, the overall mass 
357 of piperacillin a patient will be exposed to over a 20 year period would exceed 10kg. Thirty five percent 
358 of patients with cystic fibrosis develop delayed-type piperacillin hypersensitivity reactions 
359 characterized clinically with maculopapular or urticarial rashes, fever and arthralgia (105). Drug-
360 responsive T-cells are detected in approximately 75% of hypersensitive patients, but not tolerant 
361 controls using the lymphocyte transformation test (65). Moreover, CD4+ and CD8+ T-cells that secrete 
362 proinflammatory cytokines, including IL-22 and cytolytic molecules, when exposed to piperacillin are 
363 present in inflamed skin (2). Drug-responsive T-cells are also detectable in drug tolerant patients 
364 (unpublished data) and drug-naïve donors (2, 101), but only when immune regulation has been 































































365 perturbed ex vivo and the drug peptide adduct is presented by dendritic cells pre-treated with LPS to 
366 provide co-stimulation.
367 The mean time to onset of piperacillin hypersensitivity is the ninth day of the ninth treatment course 
368 (i.e., the average patient will tolerate eight separate courses of piperacillin), which might lead one to 
369 assume that susceptibility is linked to accumulation of, or repeated exposure to, the drug peptide 
370 complex. However, over a 20 year assessment period at the St. James Cystic Fibrosis Unit (Leeds, UK) 
371 patients have been diagnosed with hypersensitivity after every treatment course (1-15; personnel 
372 communication, Dr Paul Whitaker). These clinical data are impossible to rationalize in terms of drug 
373 exposure/accumulation, the availability of a T-cell repertoire for the drug peptide complex or indeed 
374 a single genetic factor such as HLA. 
375 As depicted in figure 2, the pathway of T-cell activation for drugs such as allopurinol and 
376 carbamazepine are very different to that of -lactam antibiotics. It is possible that reactions with these 
377 drugs occur after T-cell responses develop in the presence of other classical peptide antigens (i.e., the 
378 drug peptide complex cross-reacts with the peptide antigen). In this case, the drug will not always 
379 activate a de novo response for hypersensitivity to develop and the regulatory requirements for 
380 activation will be lower. The caveat to this argument however is that both of these drugs have been 
381 shown to prime naïve T-cells using autologous dendritic cells to present the drug peptide complex in 
382 an appropriate immunological form (108).    
383 The immune regulatory network
384 Several mechanisms have evolved to regulate T-cell responses and prevent the development of 
385 autoimmune disease and other inflammatory conditions. The best known mechanisms of peripheral 
386 tolerance include thymic selection of T-cells, the suppressive activity of Tregs (109) and the increased 
387 expression of cell surface receptors, the so-called immune checkpoints (110, 111). The importance of 
388 immune regulation and power of the regulatory network has been demonstrated clinically through 
389 the application of immune checkpoint inhibitors for the treatment of cancer (112). Furthermore, 
390 mutations in FOXP3, the regulatory transcription factor for Tregs, results in dysfunctional Tregs and 
391 the development of autoimmune disease and allergy (113). IPEX syndrome – a loss of function 
392 mutation in FOXP3 (and other regulatory pathways such as CTLA4) - is the most extreme clinical 
393 scenario. IPEX syndrome is often fatal presenting clinically for a variety of autoimmune-like 
394 syndromes. It would be interesting to investigate whether patients with IPEX syndrome also develop 
395 more drug hypersensitivity reactions. Tregs are now easy to expand ex vivo and have been used in 
396 Phase I clinical trials for the treatment of autoimmune disease to prevent transplant rejection (114). 































































397 In the following sections we briefly discuss the major immune regulatory pathways and how 
398 dysregulation of these pathways may impact on drug hypersensitivity. 
399
400 Immune checkpoints     
401 Immune checkpoints are a series of receptor ligand interactions between T-cells and antigen 
402 presenting/tissue cells which specifically co-ordinate the secondary co-stimulatory signal required for 
403 immune activity following TCR binding. Checkpoint proteins negatively regulate the activation of naïve 
404 T-cells. Furthermore, checkpoint receptor expression is upregulated on T-cells when they are 
405 activated, providing a negative feedback loop to restrict the effector response. PD-1 and CTLA-4, which 
406 are expressed on T-cells, are the most studied immune checkpoints. PD-1 interacts with ligands PD-L1 
407 and PD-L2, which activates tyrosine phosphatases that inactivate tyrosine kinase-mediated activation 
408 signals (115). CTLA-4 binds to ligands CD80 and CD86 on antigen presenting cells displaying antigen. 
409 T-cell inhibition is achieved through competitive antagonism of CD28 signalling and direct delivery of 
410 an intracellular signal (116). Other less well characterized immune checkpoints include TIM-3 
411 (suppresses Th1/Th17 CD4+ responses (117)) and LAG-3 (contributes towards Treg activity and directly 
412 suppresses CD8+ T-cells (118)). The complex interaction between immune checkpoints and naïve and 
413 memory T-cell subsets and how intra- and inter-individual variation impacts on susceptibility to 
414 adverse immunological reactions is ill-defined. 
415 In recent years, we have investigated whether receptor blockade with immune checkpoint inhibitors 
416 remove the immune brakes and enhance the priming of naïve T-cells by drugs. Naïve T-cells were 
417 cultured in vitro with drug and autologous dendritic cells in the presence and absence of immune 
418 checkpoint inhibitors targeting PD-1, CTLA-4 and Tim-3 for 14 days to allow priming to occur. Drug 
419 exposure was associated with an increase in expression of all three immune checkpoints on dividing 
420 T-cells during the culture period, presumably a regulatory event to keep the drug-specific response in 
421 check (119). After the 14 day culture period, the primed T-cells were restimulated with drug and a 
422 second batch of autologous dendritic cells and the strength of the T-cell response was assessed. PD-1 
423 and CTLA-4 block enhanced the priming of naïve T-cells to drugs, whereas Tim-3 block had no effect 
424 (102, 119). A similar effect (enhanced priming of naïve T-cells to drugs) has been demonstrated in vivo 
425 with PBMC from patients receiving immune checkpoint inhibitor therapy (unpublished data). 
426 Furthermore, it is becoming apparent that patients receiving immune checkpoint inhibitor therapy 
427 develop more frequent drug hypersensitivity reactions. Ford et al. (120) recently described the 
428 development of sulfasalazine (a combination of salicylic acid and sulfapyridine)-induced cutaneous 
429 hypersensitivity in 4 patients with metastatic melanoma that had previous been treated with the anti 































































430 PD-1 inhibitor pembrolizumab or the anti CTLA-4 inhibitor ipilimumab. Presumably the T-cell response 
431 and subsequent hypersensitivity reaction was induced by the sulfonamide component of sulfasalazine 
432 when natural immune checkpoints had been suppressed. Phillips et al. have recently reported on the 
433 treatment  outcomes of 285 patients that developed cutaneous adverse events attributed to immune 
434 checkpoint inhibitor therapy (121). It would be interesting to consider the number of these patients 
435 receiving concomitant therapy with low molecular weight drugs.  
436 A report of the post-approval safety of the B-raf inhibitor vemurafenib described seven patients that 
437 developed serious cutaneous hypersensitivity reactions and importantly, six of these patients received 
438 anti-PD-1 antibody therapy prior to starting vemurafenib (122). Phase II studies of ipilimumab plus or 
439 minus dacarbazine therapy concluded that ipilimumab monotherapy had a manageable adverse 
440 events profile (123), while dual therapy provided no improvement in efficacy and was not tolerable 
441 due to serious liver injury (124). Dacarbazine use alone is only associated with rare cases of liver injury 
442 (125). The immune checkpoint inhibitor again seems to alter the co-stimulatory/co-inhibitory balance, 
443 permitting the development of dacarbazine-induced liver injury in almost all treated patients. Finally, 
444 it has been reported that polymorphisms in regulatory targets of immune responses such as CTLA-4 
445 and IL-10 could modulate susceptibility to nonsteroidal anti-inflammatory drug (126) and efavirenz 
446 (127) hypersensitivity reactions. Collectively, these data indicate that immune checkpoints act to 
447 regulate the strength of the drug-specific T-cell response and hence impact on the balance between 
448 tolerance and hypersensitivity (Figure 4). These interactions will become increasingly relevant as the 
449 focus on combination therapies for the treatment of various malignancies increases. Combination 
450 therapies in oncology started by using two checkpoint inhibitors in combination (αCTLa-4/αPD-1) 
451 which illustrated increased efficacy but also an increased incidence of toxicity with a severe toxicity 
452 incidence of 56% of patients (128). Latterly there have been an increasing number of trials combining 
453 checkpoint inhibitors with additional systemic anticancer therapies including chemotherapy 
454 (KEYNOTE189 [ClinicalTrials.gov number, NCT02578680], IMpassion150 [ClinicalTrials.gov 
455 number, NCT03125902]) and tyrosine kinase inhibitors (KEYNOTE426 [ClinicalTrials.gov 
456 number, NCT02853331]). This has culminated in the use of all three agents in some anticancer regimes 
457 eg atezolizumab, bevacizumab, carboplatin and paclitaxel used in combination for the treatment of 
458 non-small cell lung cancer (NSCLC) within IMPower150 (ClinicalTrials.gov number, NCT02366143). 
459 Given the propensity for immune checkpoint inhibitors to interact and display phenotypically typical 
460 hypersensitivity reactions the ability to predict individuals at risk of hypersensitivity or particular drug 
461 combinations which carry an increased risk is increasingly important. It also remains to be seen if there 
462 is a characterizable dose-toxicity relationship or whether there is a temporal relationship to 
463 hypersensitivity. It is known that as monoclonal antibodies, immune checkpoint inhibitors have long 































































464 half-lives (6.1-25 days) (129) and receptor occupancy exists for weeks. However it is currently unclear 
465 if there is a dynamic relationship with hypersensitivity and the duration of risk. 
466 Tim-3 is an immune checkpoint receptor that interacts with its ligand galectin 9 to modulate Th1 CD4+ 
467 T-cell responses. The expression of Tim-3 has recently been shown to be significantly reduced on 
468 peripheral blood CD4+ T-cells in the acute phase of drug-induced manculopapular exanthema (130), 
469 a classical Th1-mediated iatrogenic disease. Furthermore, galectin 9 expression and release was 
470 reduced on dendritic cells. These data indicate that the Tim-3 immune checkpoint also contributes to 
471 the maintenance of drug tolerance and the prevention of hypersensitivity reactions. 
472 Contact allergy is a CD8+ T-cell mediated delayed-type hypersensitivity reaction brought about by low 
473 molecular weight haptens. Unlike drug hypersensitivity, where for the most part murine models do 
474 not exist, contact allergy can be reproduced easily in mice through direct application of the hapten to 
475 skin. In recent years, contact allergy has been used to explore how Toll-like receptors, the 
476 inflammasome and endogenous danger signals impact on the hapten specific CD8+ T-cell response 
477 and skin inflammation (131-135). Most recently, Gamradt et al., (136) discovered that intrinsic control 
478 mechanisms such as immune regulatory (PD-1 and TIM-3) signalling determine whether the cytotoxic 
479 CD8+ T-cells will be reactivated and hence prevent tissue injury. Blocking of immune checkpoints in 
480 vivo lead to severe contact hypersensitivity responses with low hapten doses. 
481 Immune checkpoint blockade has been used in mice to attempt to develop animal models of drug-
482 induced liver injury with a delayed onset (137-140). Treatment of mice with therapeutic doses of 
483 human liver injury inducing compounds such as amodiaquine, isoniazid and nevirapine did not result 
484 in significant tissue damage. However, when the drugs were administered in the presence of PD-1 and 
485 CTLA-4 block, mild, but significant, delayed onset liver injury was observed. Liver injury was associated 
486 with hepatic recruitment of immune cells including CD8+ T-cells, suggesting that they participate in 
487 the pathogenesis. Although this work represents an important step forward – an in vivo model is now 
488 available to begin to study drug-induced delayed-typed liver injury - additional studies are required to 
489 determine why the liver injury does not progress to the serious forms of tissue damage seen in human 
490 patients. 
491 From the above discussion one can begin to visualize how immune checkpoint signalling impacts on 
492 the co-regulatory/co-stimulatory network that determines whether an effector response will ensue 
493 following antigen exposure as well as the strength and duration of the response. As one pathway is 
494 blocked other pathways exert an increased influence in an attempt to maintain tolerance. As we move 
495 forward combined immune checkpoint therapy will become more commonplace. This will result in an 































































496 increase in serious autoimmune side effects. However, it is highly likely that drug hypersensitivity 
497 reactions will also become more prevalent.     
498
499 Regulatory T-cells (Tregs)
500 Tregs regulate or suppress other cells in the immune system. They control the immune response to 
501 self and foreign antigens and help prevent autoimmune disease and allergy. Natural Tregs are 
502 identified by expression of the regulatory transcription factor FOXP3. Natural Tregs express CD4+ and 
503 CD25+ (141); however, CD25+ is also expressed on other forms of T-cell including activated T-cells. 
504 Thus, there was a search for additional classification markers. CD127+ has been identified as a marker 
505 that is only expressed at low levels on Tregs and can be used alongside CD4+, CD25+ and FOXP3 to 
506 identify natural Tregs (142, 143). Tregs can also be classified according to the expression of a naïve T-
507 cell marker CD45RA (144). CD45RA+FOXP3lowCD4+ (CTLA-4low, CD25high, CD127low) cells are referred to 
508 as naïve or inducible Tregs. These cells exhibit weak suppressive activity until they differentiate 
509 following antigen-mediated T-cell receptor engagement. They differentiate into effector Tregs 
510 (CD45RA-FOXP3highCD4+) that display a range of additional markers including CTLA-4, CD25+, PD-1, 
511 TIM-3 and secretory molecules such as IL-10 and TGF-. These cells display a strong inhibitory activity 
512 and increase in number in blood with age. Tregs exert their suppressive function through a range of 
513 pathways ((144-146) Figure 5). These include the inhibition of antigen presenting cells through 
514 expression of immune checkpoint receptors, the release of cytokines such as IL-10 and TGF- that 
515 decrease dendritic cell function and the production of pro-inflammatory cytokines and restriction of 
516 IL-2 for effector T-cells through CD25+ ligation. 
517 A plethora of studies have shown that FOXP3+ Tregs suppress hypersensitivity reactions to chemical 
518 contact allergens in mice by blocking effector CD8+ T-cell responses (147-149). Gomez de Aguero et 
519 al (150) reported that Langerhans cells (cutaneous dendritic cells) are critical in the regulatory process 
520 through inducing the depletion of antigen-responsive T-cells and by activating FOXP3+ Tregs. 
521 Furthermore, in vivo expansion of Treg populations has been shown to induce long-term suppression 
522 of contact hypersensitivity (151). In humans, Cavani et al (152) hasve reported that CD25+ regulatory 
523 T-cells maintain tolerance to the contact metal allergen nickel in non-hypersensitive individuals. T-
524 cells showed a limited capacity to proliferate in the presence of nickel ex vivo. However, T-cell 
525 activation was strongly increased when Tregs were depleted from the PBMC population. Collectively, 
526 the data generated showed that Tregs blocked the efficient activation of naïve and memory nickel-
527 specific T-cells. It will be interesting to see whether similar pathways (possibly when Tregs are 
528 depleted alongside checkpoint inhibition) are active in drug tolerant patients.































































529 In in vitro T-cell priming assays with PBMC from healthy human donors, the depletion of FOXP3+ Tregs 
530 is important to detect CD4+ and CD8+ T-cell responses to drugs and haptenic chemicals (100, 153, 
531 154). The reintroduction of Tregs to naïve T-cell priming assays block the activation of naïve T-cells by 
532 drugs in a cell concentration-dependent manner (119). Inducible effector Tregs (presumably drug 
533 peptide complex-responsive) are generated in vitro alongside effector CD4+ and CD8+ T-cells during 
534 the priming of naïve T-cells (unpublished data), further emphasizing their importance at regulating 
535 drug-specific immune responses. There is a potential for environmental and genetic factors to 
536 modulate the expression and activity of Tregs. For example, polymorphic variants of FOXP3 have been 
537 linked to various forms of autoimmune disease, while exposure to air pollution can methylate the 
538 FOXP3 locus, compromising Treg function (155-158). Thus, Tregs might be important in maintaining 
539 an effective level of tolerance in all drug-exposed patients. 
540 Little is known about the influence of Tregs and Treg dysregulation in the acute phase of a drug 
541 hypersensitivity reaction. In patients with toxic epidermal necrolysis, the most severe form of 
542 blistering skin eruption, Takahashi et al described a functional impairment of Tregs and a reduced 
543 capacity to suppress effector T-cell responses to drugs (159, 160). However, the key mechanisms 
544 implicit in Treg dysregulation were not defined. Recently, Wang et al. demonstrated that treatment 
545 with a TNF- antagonist reduced skin healing time in patients with severe forms of toxic epidermal 
546 necrolysis (161). Drug treatment decreased TNF- and granulysin levels in blister fluid and significantly 
547 increased Treg proportions in patients during the recovery phase.  In patients with a different form of 
548 severe cutaneous hypersensitivity reaction, DRESS, CD14+ monocytes have been shown to mediate a 
549 gradual shift from a Treg to a Th17 phenotype during the course of the disease (162). In an 
550 independent study, lesional skin of patients with DRESS was found to be rich in FOXP3+ cells and the 
551 increase in Tregs positively correlated with the number of recorded days from the onset of the disease 
552 (163). Similarly, Hanafusa et al, found a switch in the population of dividing cells from CD8+ to FOXP3+ 
553 Tregs in drug-treated PBMC from a patient with DRESS (164). Collectively, these data indicate that the 
554 Tregs are being activated and recruited to inflamed skin to attempt to control the strength and 
555 duration of the drug-specific effector T-cell response. Thus, it is important to develop strategies to 
556 understand the role Tregs play in determining the outcome of drug exposure in patients. 
557 Recently, breaking tolerance through depletion of murine CD4+ T-cells was found to result in the 
558 development of abacavir hypersensitivity in a HLA-B*57:01 transgenic model (165). Abacavir exposure 
559 per se induced a CD8+ T-cell response; however, the mice maintained an anergic disease state. An 
560 adverse reaction in skin was only detected when CD4+ T-cells, which included Tregs, were depleted.  
561 The epidermis became heavily infiltrated with CD8+ T-cells and skin showed typical signs of tissue 
562 injury. The authors demonstrated through a series of detailed experiments that CD4+ T-cell depletion 































































563 resulted in optimal dendritic cell co-stimulation and a break in regulation, predisposing the mice to 
564 tissue injury.         
565
566 Cytokines
567 During T-cell priming, naïve CD4+ T-cells differentiate into one of several linages, including Th1, Th2, 
568 Th17, Th22 and induced Tregs. Each T-cell population is characterized by the cytokines they secrete 
569 when activated. Importantly, the cytokine microenvironment during T-cell receptor triggering controls 
570 T-cell differentiation (Figure 6). The impact of the cytokine microenvironment on T-cell polarization 
571 can be demonstrated experimentally by culturing purified human T-cells with relevant cytokine 
572 cocktails (Th1, IL-12 & anti-IL-4; Th2, IL-4, anti-IL-12 & anti-IFN-; Th17, IL-1, IL-6, IL-23 & TGF-; Th22, 
573 TNF- & IL-6) for 7 days pri r to non-specific mitogen stimulation. Activated T-cells secrete the 
574 polarized cytokines illustrated in Figure 6. The activation of CD8+ T-cells is also influenced by cytokines. 
575 In the absence of specific cytokine signals, CD8+ T-cells become anergic and unresponsive to antigen 
576 stimulation. The dominant cytokines that promote CD8+ T-cell activation are IL-12 and IFN-/ (166, 
577 167). 
578 There are many examples of disease induced cytokine imbalance (168-170) and this could have a 
579 major impact on the outcome of drug exposure. Diseases such as HIV and cystic fibrosis predispose 
580 individuals to drug hypersensitivity reactions. In patients with HIV the incidence of sulfonamide 
581 hypersensitivity is 10 times higher when compared with non-HIV infected patients (171). Cytokine 
582 imbalances such as Th1/Th2 switching are common features in patients with HIV as the disease 
583 progresses (172), but to date the impact of these changes on susceptibility to drug hypersensitivity 
584 has not been studied. Similarly, when patients with cystic fibrosis were compared to the general 
585 population, antibiotic reactions were found to be up to three times more common (105). The cystic 
586 fibrosis lung represents an area of chronic inflammation with high neutrophil numbers alongside 
587 elevated levels of cytokines such as IL-8, IL-1, IL-6, IL-17 and TNF- (173-175). Obviously, this will 
588 have a colossal impact on the outcome of T-cell receptor triggering through altered antigen 
589 presentation as well as differential polarization of the effector T-cell response. However, to date, it 
590 has not been possible to establish models/systems to explore this relationship directly.        
591         
592 Conclusions      
593 It is becoming increasingly apparent that multiple tolerance pathways determine the outcome of 
594 antigen exposure through regulation of (i) naïve T-cell activation and (ii) the strength and duration of 































































595 the effector T-cell response. Through the studies discussed herein we are beginning to understand 
596 that similar pathways are active in patients at the time of drug exposure and that immune regulation 
597 networks contribute towards the outcome of drug exposure: health benefit or a hypersensitivity 
598 reaction. Work is required to define how the distinct pathways contribute towards individual 
599 susceptibility. Such studies are urgent given the plethora of immune modulatory drugs that are in 
600 development, which once approved will be administered alongside traditional low molecular weight 
601 drugs. It will also be important to determine whether low molecular weight drugs modulate tolerance 
602 pathways in patients and whether this contributes to the successful desensitization of certain 
603 hypersensitive patients.            
































































605 Table 1. HLA class I allele-associated drug hypersensitivity reactions with known drug HLA binding 
606 interactions for T-cell activation 




Abacavir hypersensitivity HLA-B*57:01 (7) Direct non-covalent binding 
(9, 176)
Yes, aldehyde (177)











Direct labile drug & 
metabolite binding (178, 
179)
Yes, multiple metabolites 
(180, 181)
Carbmazepine skin reactions HLA-A*31:01 
(91)
Direct labile drug & 
metabolite binding (178, 
179)
Yes, multiple metabolites 
(180, 181)
Dapsone drug reaction with 




Direct labile & metabolite 
covalent binding (17, 182)
Yes, nitroso metabolite 
(183, 184)
Flucloxacillin liver injury HLA-B*57:01 
(88)







Direct labile & metabolite 
covalent binding (4, 76, 77)
Yes, nitroso metabolite 
(185)
Co-amoxiclav liver injury HLA-A*02:01 
(92)
Direct covalent binding  (42) Not applicable (53)
Minocycline liver injury HLA-B*35:02 
(94)
Unknown Yes, quinone iminium ion 
(186)
Terbinafine liver injury HLA-A*33:01 
(95)
Unknown Yes, aldehyde metabolite 
(187)
Ticlopidine liver injury HLA-A*33:03 
(188)
Direct labile binding (189) Yes, sulfenic acid (190)
Vancomycin drug reaction 






608 aalternative pathways feasible for all compounds, but to date have not been studied
609 bformation of a metabolite does not indicate that they are involved in the reaction
































































611 Figure 1. The drug hypersensitivity susceptibility conundrum proposes that if we assume exposure to 
612 a drug and the availability of HLA proteins and T-cell receptors for drug peptide complexes are kept as 
























































































619 Figure 2. The influence of drug- and patient-specific factors on drug immunogenicity and 
620 hypersensitivity.  Drug exposure and the availability of HLA proteins and T-cell receptors for drug 
621 binding are essential for immunogenicity. However, these factors either together or in isolation do not 
622 predict whether a patient will develop hypersensitivity. This is because immune regulatory pathways 
623 control whether a pathogenic immune response will develop. These pathways may influence p-I and 
624 hapten responses to different extents although this is yet to be proven even in the case of abacavir. 
625 The bottom component of the figure highlights the nature of the drug immune receptor binding 
626 interaction, the requirement for antigen processing and the derivative that T-cell receptors interact 

























Non-covalent to HLA, 
peptide or TCR 
























































































632 Figure 3. The balance between co-stimulatory and co-inhibitory pathways are the key determinant of 
633 whether drug exposure will result in hypersensitivity. This balance is influenced by genetic, disease 
634 and environmental factors. Thus, the balance will differ across individuals and within the same 
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637 Figure 4. Co-inhibitory receptors regulate the strength of the drug-specific T-cell response and hence 














• Enhanced cytokine release
• Enhanced cytotoxicity































































641 Figure 5. Tregs regulate the strength of antigen-specific effector T-cell responses and hence may alter 
642 the balance between tolerance and hypersensitivity following drug exposure.
643
Tregs:
Tregs produced in the thymus 
are termed natural
Treg formed by differentiation 
of naïve T cells outside the 





• Apoptosis of effector cells
• Modulation of DC function






• Decrease in T-cell proliferation
• Decrease in MHC and co-stimulatory molecules
• Decrease in APC function
• Decrease in inflammatory cytokines
Cell-cell contact 
(eg. CTLA-4)




































































644 Figure 6. Cytokine control of T-cell differentiation.
645
646
Th1 Th2 Th17 Th22 Treg





































































































649 Text box 1. Major Milestone Discoveries 
650  Drug, drug metabolite and drug-modified peptide HLA binding activates T-cells in 
651 patients with hypersensitivity
652  Development of assays with PBMC from healthy human donors to study naïve drug 
653 peptide complex T-cell priming ex vivo
654  Individual HLA alleles are important determinants of disease susceptibility
655  Characterisation of HLA-allele-restricted drug-specific T-cell responses in patients with 
656 drug hypersensitivity.
657  Co-inhibitory receptors impact on the ability of drug peptide complexes to activate naïve 
658 T-cells
659  Discovery of an increased incidence of drug hypersensitivity reactions in patients 
660 receiving immune checkpoint inhibitor therapy  
661
662 Text Box 2. Future Research Perspectives
663 Genome-wide association studies and functional assessment of patient T-cells have taught us that 
664 drug peptide complexes interact selectively and specificity with HLA proteins to bring about 
665 hypersensitivity reactions. It is now important to define, through detailed structural analysis, the way 
666 in which drug peptide complexes bind to HLA proteins. The nature of the interaction will differ drug-
667 to-drug. It is also important to determine the contribution different forms of drug peptide complex 
668 play in the disease pathogenesis as we know that parent drug, metabolite and drug-modified peptide-
669 responsive T-cells circulate in patients’ blood and tissues.  
670 Of particular importance, is identification of the parameters that that influence susceptibility in 
671 patients expressing known HLA risk alleles. Ongoing studies seem to suggest that drugs stimulate a 
672 very restricted repertoire of T-cells in patients with Stevens Johnson syndrome. Might this be the case 
673 in other forms of drug hypersensitivity? The balance between co-stimulatory and co-inhibitory 
674 signalling during drug peptide complex-specific T-cell priming is also an important determinant of 
675 susceptibility. Future research must focus on patients at the earliest stages of a reaction to delineate 
676 the contribution individual pathways (e.g, receptor signalling, Tregs, cytokines) in play in 
677 determination of the outcome of drug exposure. In this respect, important lessons will be learned 
678 from patients receiving immune checkpoint inhibitor therapy for cancer treatment.    
679
680

































































683 1. Johansson SG, et al. (2004) Revised nomenclature for allergy for global use: Report of the 
684 Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy 
685 Clin Immunol 113(5):832-836.
686 2. Sullivan A, et al. (2018) beta-Lactam hypersensitivity involves expansion of circulating and 
687 skin-resident TH22 cells. J Allergy Clin Immunol 141(1):235-249 e238.
688 3. Britschgi M, et al. (2001) T-cell involvement in drug-induced acute generalized 
689 exanthematous pustulosis. J Clin Invest 107(11):1433-1441.
690 4. Nassif A, et al. (2004) Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T 
691 cells. J Allergy Clin Immunol 114(5):1209-1215.
692 5. Pichler WJ, et al. (2010) Drug hypersensitivity reactions: pathomechanism and clinical 
693 symptoms. Med Clin North Am 94(4):645-664, xv.
694 6. Pichler WJ (2003) Delayed drug hypersensitivity reactions. Ann Intern Med 139(8):683-693.
695 7. Mallal S, et al. (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 
696 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308):727-
697 732.
698 8. Mallal S, et al. (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 
699 358(6):568-579.
700 9. Illing PT, et al. (2012) Immune self-reactivity triggered by drug-modified HLA-peptide 
701 repertoire. Nature 486(7404):554-558.
702 10. Norcross MA, et al. (2012) Abacavir induces loading of novel self-peptides into HLA-B*57: 
703 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 26(11):F21-F29.
704 11. Ostrov DA, et al. (2012) Drug hypersensitivity caused by alteration of the MHC-presented 
705 self-peptide repertoire. Proc Natl Acad Sci U S A 109(25):9959-9964.
706 12. Lucas A, et al. (2015) Abacavir-reactive memory T cells are present in drug naive individuals. 
707 PLoS One 10(2):e0117160.
708 13. Bell CC, et al. (2013) T-cells from HLA-B*57:01+ human subjects are activated with abacavir 
709 through two independent pathways and induce cell death by multiple mechanisms. Chem 
710 Res Toxicol 26(5):759-766.
711 14. Adam J, et al. (2012) Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J 
712 Immunol 42(7):1706-1716.
713 15. Monshi MM, et al. (2013) Human Leukocyte Antigen (HLA)-B(star)57:01-Restricted 
714 Activation of Drug-Specific T Cells Provides the Immunological Basis for Flucloxacillin-
715 Induced Liver Injury. Hepatology 57(2):727-739.
716 16. Wu Y, Farrell J, Pirmohamed M, Park BK, & Naisbitt DJ (2007) Generation and 
717 characterization of antigen-specific CD4(+), CD8(+), and CD4(+)CD8(+) T-cell clones from 
718 patients with carbamazepine hypersensitivity. J Allergy Clin Immunol.
719 17. Zhao Q, et al. (2019) Dapsone- and nitroso dapsone-specific activation of T-cells from 
720 hypersensitive patients expressing the risk allele HLA-B*13:01. Allergy.
721 18. Illing PT, Purcell AW, & McCluskey J (2017) The role of HLA genes in pharmacogenomics: 
722 unravelling HLA associated adverse drug reactions. Immunogenetics 69(8-9):617-630.
723 19. Negrini S & Becquemont L (2017) HLA-associated drug hypersensitivity and the prediction of 
724 adverse drug reactions. Pharmacogenomics 18(15):1441-1457.
725 20. Schutte RJ, Sun Y, Li D, Zhang F, & Ostrov DA (2018) Human Leukocyte Antigen Associations 
726 in Drug Hypersensitivity Reactions. Clin Lab Med 38(4):669-677.
727 21. Hung SI, et al. (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse 
728 reactions caused by allopurinol. Proc Natl Acad Sci U S A 102(11):4134-4139.































































729 22. Roychowdhury S, Cram AE, Aly A, & Svensson CK (2007) Detection of haptenated proteins in 
730 organotypic human skin explant cultures exposed to dapsone. Drug Metab Dispos 
731 35(9):1463-1465.
732 23. Rijal JP, Pompa T, Giri S, & Bhatt VR (2014) A case of toxic epidermal necrolysis caused by 
733 trimethoprim-sulfamethoxazole. BMJ Case Rep 2014.
734 24. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, & Roujeau JC (2000) Toxic epidermal 
735 necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs 
736 decrease the risk of death? Arch Dermatol 136(3):323-327.
737 25. Hunziker T, Kunzi UP, Braunschweig S, Zehnder D, & Hoigne R (1997) Comprehensive 
738 hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 
739 52(4):388-393.
740 26. Roujeau JC (2005) Clinical heterogeneity of drug hypersensitivity. Toxicology 209(2):123-129.
741 27. Ye YM, et al. (2017) Drug-specific CD4(+) T-cell immune responses are responsible for 
742 antituberculosis drug-induced maculopapular exanthema and drug reaction with 
743 eosinophilia and systemic symptoms syndrome. Br J Dermatol 176(2):378-386.
744 28. Feldmeyer L, Heidemeyer K, & Yawalkar N (2016) Acute Generalized Exanthematous 
745 Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy. Int J Mol Sci 
746 17(8).
747 29. Spriet S & Banks TA (2015) Drug reaction with eosinophilia and systemic symptoms 
748 syndrome. Allergy Asthma Proc 36(6):501-505.
749 30. Uetrecht J & Naisbitt DJ (2013) Idiosyncratic adverse drug reactions: current concepts. 
750 Pharmacol Rev 65(2):779-808.
751 31. Choquet-Kastylevsky G, et al. (1998) Increased levels of interleukin 5 are associated with the 
752 generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol 
753 139(6):1026-1032.
754 32. Descamps V, et al. (1997) Human herpesvirus 6 infection associated with anticonvulsant 
755 hypersensitivity syndrome and reactive haemophagocytic syndrome. Br J Dermatol 
756 137(4):605-608.
757 33. Suzuki Y, Inagi R, Aono T, Yamanishi K, & Shiohara T (1998) Human herpesvirus 6 infection as 
758 a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch 
759 Dermatol 134(9):1108-1112.
760 34. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, & Harr T (2018) Current Perspectives on 
761 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allergy Immunol 
762 54(1):147-176.
763 35. Gahr M, et al. (2016) Drug-Induced Liver Injury Associated With Antidepressive 
764 Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection 
765 Using Different MedDRA Terms. Journal of clinical pharmacology 56(6):769-778.
766 36. Suk KT & Kim DJ (2012) Drug-induced liver injury: present and future. Clinical and molecular 
767 hepatology 18(3):249-257.
768 37. Leise MD, Poterucha JJ, & Talwalkar JA (2014) Drug-induced liver injury. Mayo Clinic 
769 proceedings 89(1):95-106.
770 38. Hoofnagle JH & Bjornsson ES (2019) Drug-Induced Liver Injury - Types and Phenotypes. N 
771 Engl J Med 381(3):264-273.
772 39. Andrade RJ, et al. (2006) Outcome of acute idiosyncratic drug-induced liver injury: Long-term 
773 follow-up in a hepatotoxicity registry. Hepatology 44(6):1581-1588.
774 40. Daly AK & Day CP (2012) Genetic association studies in drug-induced liver injury. Drug Metab 
775 Rev 44(1):116-126.
776 41. Usui T, et al. (2017) From the Cover: Characterization of Isoniazid-Specific T-Cell Clones in 
777 Patients with anti-Tuberculosis Drug-Related Liver and Skin Injury. Toxicol Sci 155(2):420-
778 431.































































779 42. Kim SH, et al. (2015) Characterization of amoxicillin- and clavulanic acid-specific T cells in 
780 patients with amoxicillin-clavulanate-induced liver injury. Hepatology 62(3):887-899.
781 43. Monshi MM, et al. (2013) Human leukocyte antigen (HLA)-B*57:01-restricted activation of 
782 drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. 
783 Hepatology 57(2):727-739.
784 44. Wuillemin N, et al. (2014) T Cells Infiltrate the Liver and Kill Hepatocytes in HLA-B( *)57:01-
785 Associated Floxacillin-Induced Liver Injury. Am J Pathol 184(6):1677-1682.
786 45. Mennicke M, et al. (2009) Fulminant liver failure after vancomycin in a sulfasalazine-induced 
787 DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant 9(9):2197-
788 2202.
789 46. Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, & Park BK (2000) Induction of 
790 metabolism-dependent and -independent neutrophil apoptosis by clozapine. Molecular 
791 pharmacology 58(1):207-216.
792 47. Guest I & Uetrecht J (1999) Drugs that induce neutropenia/agranulocytosis may target 
793 specific components of the stromal cell extracellular matrix. Med Hypotheses 53(2):145-151.
794 48. Christie G, Breckenridge AM, & Park BK (1989) Drug-protein conjugates--XVIII. Detection of 
795 antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man 
796 and the rat. Biochem Pharmacol 38(9):1451-1458.
797 49. Jaunkalns R, et al. (1992) Antimyeloperoxidase antibodies and adverse reactions to 
798 clozapine. Lancet 339(8809):1611-1612.
799 50. Uetrecht J (2019) Mechanisms of idiosyncratic drug-induced liver injury. Adv Pharmacol 
800 85:133-163.
801 51. Batchelor FR, Dewdney JM, & Gazzard D (1965) Penicillin allergy: the formation of the 
802 penicilloyl determinant. Nature 206:362-364.
803 52. Jenkins RE, et al. (2009) Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin 
804 haptenated HSA in vitro and in vivo. Proteomics Clinical Applications 3(6):720-729.
805 53. Meng X, et al. (2016) Amoxicillin and Clavulanate Form Chemically and Immunologically 
806 Distinct Multiple Haptenic Structures in Patients. Chem Res Toxicol 29(10):1762-1772.
807 54. Whitaker P, et al. (2011) Mass spectrometric characterization of circulating and functional 
808 antigens derived from piperacillin in patients with cystic fibrosis. J Immunol 187(1):200-211.
809 55. Sanchez-Gomez FJ, et al. (2017) Amoxicillin haptenates intracellular proteins that can be 
810 transported in exosomes to target cells. Allergy 72(3):385-396.
811 56. Ariza A, et al. (2014) Study of protein haptenation by amoxicillin through the use of a 
812 biotinylated antibiotic. PLoS One 9(3):e90891.
813 57. Ogese MO, et al. (2019) Exosomal transport of hepatocyte-derived drug-modified proteins 
814 to the immune system. Hepatology.
815 58. Padovan E, Bauer T, Tongio MM, Kalbacher H, & Weltzien HU (1997) Penicilloyl peptides are 
816 recognized as T cell antigenic determinants in penicillin allergy. Eur J Immunol 27(6):1303-
817 1307.
818 59. Brander C, et al. (1995) Heterogeneous T cell responses to beta-lactam-modified self-
819 structures are observed in penicillin-allergic individuals. J Immunol 155(5):2670-2678.
820 60. Wuillemin N, et al. (2013) HLA haplotype determines hapten or p-i T cell reactivity to 
821 flucloxacillin. J Immunol 190(10):4956-4964.
822 61. El-Ghaiesh S, et al. (2012) Characterization of the antigen specificity of T-cell clones from 
823 piperacillin-hypersensitive patients with cystic fibrosis. J Pharmacol Exp Ther 341(3):597-610.
824 62. Yaseen FS, et al. (2015) Promiscuous T-cell responses to drugs and drug-haptens. J Allergy 
825 Clin Immunol.
826 63. Meng X, et al. (2017) Definition of the Nature and Hapten Threshold of the beta-Lactam 
827 Antigen Required for T Cell Activation In Vitro and in Patients. J Immunol 198(11):4217-4227.































































828 64. Meng X, et al. (2011) Direct evidence for the formation of diastereoisomeric 
829 benzylpenicilloyl haptens from benzylpenicillin and benzylpenicillenic acid in patients. J 
830 Pharmacol Exp Ther 338(3):841-849.
831 65. Whitaker P, et al. (2011) Mass Spectrometric Characterization of Circulating and Functional 
832 Antigens Derived from Piperacillin in Patients with Cystic Fibrosis. Journal of Immunology 
833 187(1):200-211.
834 66. Beeler A, Zaccaria L, Kawabata T, Gerber BO, & Pichler WJ (2008) CD69 upregulation on T 
835 cells as an in vitro marker for delayed-type drug hypersensitivity. Allergy 63(2):181-188.
836 67. Pichler WJ & Tilch J (2004) The lymphocyte transformation test in the diagnosis of drug 
837 hypersensitivity. Allergy 59(8):809-820.
838 68. Nyfeler B & Pichler WJ (1997) The lymphocyte transformation test for the diagnosis of drug 
839 allergy: sensitivity and specificity. Clin Exp Allergy 27:175-181.
840 69. Zanni MP, et al. (1998) HLA-restricted, processing- and metabolism-independent pathway of 
841 drug recognition by human alpha beta T lymphocytes. J Clin Invest 102(8):1591-1598.
842 70. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, & Pichler WJ (1997) Direct, MHC-
843 dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J 
844 Clin Invest 100(1):136-141.
845 71. Yun J, et al. (2014) Oxypurinol directly and immediately activates the drug-specific T cells via 
846 the preferential use of HLA-B*58:01. J Immunol 192(7):2984-2993.
847 72. Wu Y, et al. (2006) Activation of T cells by carbamazepine and carbamazepine metabolites. J 
848 Allergy Clin Immun 118(1):233-241.
849 73. Naisbitt DJ, et al. (2003) Hypersensitivity reactions to carbamazepine: characterization of the 
850 specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 
851 63(3):732-741.
852 74. Adam J, et al. (2014) Abacavir induced T cell reactivity from drug naive individuals shares 
853 features of allo-immune responses. PLoS One 9(4):e95339.
854 75. Yaseen FS, et al. (2015) Promiscuous T-cell responses to drugs and drug-haptens. J Allergy 
855 Clin Immunol 136(2):474-476 e478.
856 76. Schnyder B, et al. (2000) Recognition of sulfamethoxazole and its reactive metabolites by 
857 drug-specific CD4+ T cells from allergic individuals. J Immunol 164(12):6647-6654.
858 77. Castrejon JL, et al. (2010) Stimulation of human T cells with sulfonamides and sulfonamide 
859 metabolites. J Allergy Clin Immunol 125(2):411-418 e414.
860 78. Wong IC, Mawer GE, & Sander JW (1999) Factors influencing the incidence of lamotrigine-
861 related skin rash. Ann Pharmacother 33(10):1037-1042.
862 79. Gibson A, Ogese M, & Pirmohamed M (2018) Genetic and nongenetic factors that may 
863 predispose individuals to allergic drug reactions. Curr Opin Allergy Clin Immunol 18(4):325-
864 332.
865 80. Su SC, et al. (2019) HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in 
866 East Asians. Clin Pharmacol Ther 105(2):476-485.
867 81. Hung SI, et al. (2010) Common risk allele in aromatic antiepileptic-drug induced Stevens-
868 Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 
869 11(3):349-356.
870 82. Yun J, et al. (2013) Allopurinol hypersensitivity is primarily mediated by dose-dependent 
871 oxypurinol-specific T cell response. Clin Exp Allergy 43(11):1246-1255.
872 83. Chung WH, et al. (2015) Insights into the poor prognosis of allopurinol-induced severe 
873 cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of 
874 oxypurinol and granulysin. Ann Rheum Dis 74(12):2157-2164.
875 84. Uetrecht J (2007) Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol 
876 Toxicol 47:513-539.
877 85. Lammert C, et al. (2008) Relationship between daily dose of oral medications and 
878 idiosyncratic drug-induced liver injury: search for signals. Hepatology 47(6):2003-2009.































































879 86. Pirmohamed M, Ostrov DA, & Park BK (2015) New genetic findings lead the way to a better 
880 understanding of fundamental mechanisms of drug hypersensitivity. J Allergy Clin Immunol 
881 136(2):236-244.
882 87. Pavlos R, et al. (2015) T cell-mediated hypersensitivity reactions to drugs. Annu Rev Med 
883 66:439-454.
884 88. Daly AK, et al. (2009) HLA-B*5701 genotype is a major determinant of drug-induced liver 
885 injury due to flucloxacillin. Nat Genet 41(7):816-819.
886 89. Chung WH, et al. (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 
887 428(6982):486.
888 90. Zhang FR, et al. (2013) HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J 
889 Med 369(17):1620-1628.
890 91. McCormack M, et al. (2011) HLA-A*3101 and carbamazepine-induced hypersensitivity 
891 reactions in Europeans. N Engl J Med 364(12):1134-1143.
892 92. Lucena MI, et al. (2011) Susceptibility to amoxicillin-clavulanate-induced liver injury is 
893 influenced by multiple HLA class I and II alleles. Gastroenterology 141(1):338-347.
894 93. Lonjou C, et al. (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic 
895 epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18(2):99-107.
896 94. Urban TJ, et al. (2017) Minocycline hepatotoxicity: Clinical characterization and identification 
897 of HLA-B *35:02 as a risk factor. J Hepatol 67(1):137-144.
898 95. Fontana RJ, et al. (2018) The role of HLA-A*33:01 in patients with cholestatic hepatitis 
899 attributed to terbinafine. J Hepatol 69(6):1317-1325.
900 96. Glanville J, et al. (2017) Identifying specificity groups in the T cell receptor repertoire. Nature 
901 547(7661):94-98.
902 97. Ko TM, et al. (2011) Shared and restricted T-cell receptor use is crucial for carbamazepine-
903 induced Stevens-Johnson syndrome. J Allergy Clin Immunol 128(6):1266-1276 e1211.
904 98. Pan RY, et al. (2019) Identification of drug-specific public TCR driving severe cutaneous 
905 adverse reactions. Nat Commun 10(1):3569.
906 99. Schnyder B, Adam J, Rauch A, Thurnheer MC, & Pichler WJ (2013) HLA-B*57:01(+) abacavir-
907 naive individuals have specific T cells but no patch test reactivity. J Allergy Clin Immunol 
908 132(3):756-758.
909 100. Faulkner L, et al. (2012) The development of in vitro culture methods to characterize primary 
910 T-cell responses to drugs. Toxicol Sci 127(1):150-158.
911 101. Faulkner L, et al. (2016) Detection of Primary T Cell Responses to Drugs and Chemicals in 
912 HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity. Toxicol Sci 
913 154(2):416-429.
914 102. Gibson A, et al. (2017) The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific 
915 T Cells That Express Distinct Vbeta Receptors. J Immunol 199(4):1223-1237.
916 103. Azoury ME, et al. (2018) Identification of T-cell epitopes from benzylpenicillin conjugated to 
917 human serum albumin and implication in penicillin allergy. Allergy 73(8):1662-1672.
918 104. Scornet N, et al. (2016) Bioinspired Design and Oriented Synthesis of Immunogenic Site-
919 Specifically Penicilloylated Peptides. Bioconjug Chem 27(11):2629-2645.
920 105. Whitaker P, Naisbitt D, & Peckham D (2012) Nonimmediate beta-lactam reactions in patients 
921 with cystic fibrosis. Current Opinion in Allergy and Clinical Immunology 12(4):369-375.
922 106. Parmar JS & Nasser S (2005) Antibiotic allergy in cystic fibrosis. Thorax 60(6):517-520.
923 107. Burrows JA, Toon M, & Bell SC (2003) Antibiotic desensitization in adults with cystic fibrosis. 
924 Respirology 8(3):359-364.
925 108. Usui T, et al. (2018) Application of in Vitro T Cell Assay Using Human Leukocyte Antigen-
926 Typed Healthy Donors for the Assessment of Drug Immunogenicity. Chem Res Toxicol 
927 31(3):165-167.
928 109. Wing K & Sakaguchi S (2010) Regulatory T cells exert checks and balances on self tolerance 
929 and autoimmunity. Nat Immunol 11(1):7-13.































































930 110. Ishida Y, Agata Y, Shibahara K, & Honjo T (1992) Induced expression of PD-1, a novel member 
931 of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 
932 11(11):3887-3895.
933 111. Brunet JF, et al. (1987) A new member of the immunoglobulin superfamily--CTLA-4. Nature 
934 328(6127):267-270.
935 112. Ribas A & Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 
936 359(6382):1350-1355.
937 113. Bennett CL, et al. (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-
938 linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27(1):20-21.
939 114. Todryk S, Jozwik A, de Havilland J, & Hester J (2019) Emerging Cellular Therapies: T Cells and 
940 Beyond. Cells 8(3).
941 115. Boussiotis VA (2016) Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N 
942 Engl J Med 375(18):1767-1778.
943 116. Teft WA, Kirchhof MG, & Madrenas J (2006) A molecular perspective of CTLA-4 function. 
944 Annu Rev Immunol 24:65-97.
945 117. Hastings WD, et al. (2009) TIM-3 is expressed on activated human CD4+ T cells and regulates 
946 Th1 and Th17 cytokines. Eur J Immunol 39(9):2492-2501.
947 118. Huang CT, et al. (2004) Role of LAG-3 in regulatory T cells. Immunity 21(4):503-513.
948 119. Gibson A, et al. (2014) Negative regulation by PD-L1 during drug-specific priming of IL-22-
949 secreting T cells and the influence of PD-1 on effector T cell function. J Immunol 
950 192(6):2611-2621.
951 120. Ford M, Sahbudin I, Filer A, Steven N, & Fisher BA (2018) High proportion of drug 
952 hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated 
953 inflammatory arthritis. Rheumatology (Oxford) 57(12):2244-2246.
954 121. Phillips GS, et al. (2019) Treatment Outcomes of Immune-Related Cutaneous Adverse 
955 Events. J Clin Oncol:JCO1802141.
956 122. Uhara H, Kiyohara Y, Tsuda A, Takata M, & Yamazaki N (2018) Characteristics of adverse drug 
957 reactions in a vemurafenib early post-marketing phase vigilance study in Japan. Clin Transl 
958 Oncol 20(2):169-175.
959 123. Yamazaki N, et al. (2015) Phase II study of ipilimumab monotherapy in Japanese patients 
960 with advanced melanoma. Cancer Chemother Pharmacol 76(5):997-1004.
961 124. Yamazaki N, et al. (2015) Phase II study of the immune-checkpoint inhibitor ipilimumab plus 
962 dacarbazine in Japanese patients with previously untreated, unresectable or metastatic 
963 melanoma. Cancer Chemother Pharmacol 76(5):969-975.
964 125. Dancygier H, Runne U, Leuschner U, Milbradt R, & Classen M (1983) Dacarbazine (DTIC)-
965 induced human liver damage light and electron-microscopic findings. 
966 Hepatogastroenterology 30(3):93-95.
967 126. Ferreira Vasconcelos LM, et al. (2018) Polymorphism of IL10, IL4, CTLA4, and DAO Genes in 
968 Cross-Reactive Nonsteroidal Anti-inflammatory Drug Hypersensitivity. J Clin Pharmacol 
969 58(1):107-113.
970 127. de Oliveira Rodrigues R, et al. (2017) Association of IL10, IL4, IFNG, and CTLA4 Gene 
971 Polymorphisms with Efavirenz Hypersensitivity Reaction in Patients Infected with Human 
972 Immunodeficiency Virus. Jpn J Infect Dis 70(4):430-436.
973 128. Larkin J, et al. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated 
974 Melanoma. N Engl J Med 373(1):23-34.
975 129. Sheng J, et al. (2017) Clinical Pharmacology Considerations for the Development of Immune 
976 Checkpoint Inhibitors. J Clin Pharmacol 57 Suppl 10:S26-S42.
977 130. Fernandez-Santamaria R, et al. (2019) Expression of the Tim3-galectin-9 axis is altered in 
978 drug-induced maculopapular exanthema. Allergy.
979 131. Martin SF & Jakob T (2008) From innate to adaptive immune responses in contact 
980 hypersensitivity. Curr Opin Allergy Clin Immunol 8(4):289-293.































































981 132. Martin SF, et al. (2008) Toll-like receptor and IL-12 signaling control susceptibility to contact 
982 hypersensitivity. J Exp Med 205(9):2151-2162.
983 133. Weber FC, et al. (2010) Lack of the purinergic receptor P2X(7) results in resistance to contact 
984 hypersensitivity. J Exp Med 207(12):2609-2619.
985 134. Esser PR, et al. (2012) Contact Sensitizers Induce Skin Inflammation via ROS Production and 
986 Hyaluronic Acid Degradation. PLoS One 7(7):e41340.
987 135. Schmidt M, et al. (2010) Crucial role for human Toll-like receptor 4 in the development of 
988 contact allergy to nickel. Nat Immunol 11(9):814-819.
989 136. Gamradt P, et al. (2019) Inhibitory checkpoint receptors control CD8(+) resident memory T 
990 cells to prevent skin allergy. J Allergy Clin Immunol 143(6):2147-2157 e2149.
991 137. Metushi IG, et al. (2015) Development of a novel mouse model of amodiaquine-induced liver 
992 injury with a delayed onset. J Immunotoxicol 12(3):247-260.
993 138. Mak A & Uetrecht J (2015) The Combination of Anti-CTLA-4 and PD1-/- Mice Unmasks the 
994 Potential of Isoniazid and Nevirapine To Cause Liver Injury. Chem Res Toxicol 28(12):2287-
995 2291.
996 139. Mak A & Uetrecht J (2015) The Role of CD8 T Cells in Amodiaquine-Induced Liver Injury in 
997 PD1-/- Mice Cotreated with Anti-CTLA-4. Chem Res Toxicol 28(8):1567-1573.
998 140. Metushi IG, Hayes MA, & Uetrecht J (2015) Treatment of PD-1(-/-) mice with amodiaquine 
999 and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology 
1000 61(4):1332-1342.
1001 141. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, & Toda M (1995) Immunologic self-tolerance 
1002 maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a 
1003 single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 
1004 155(3):1151-1164.
1005 142. Liu W, et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive 
1006 function of human CD4+ T reg cells. J Exp Med 203(7):1701-1711.
1007 143. Seddiki N, et al. (2006) Expression of interleukin (IL)-2 and IL-7 receptors discriminates 
1008 between human regulatory and activated T cells. J Exp Med 203(7):1693-1700.
1009 144. Togashi Y & Nishikawa H (2017) Regulatory T Cells: Molecular and Cellular Basis for 
1010 Immunoregulation. Curr Top Microbiol Immunol 410:3-27.
1011 145. Sakaguchi S, Miyara M, Costantino CM, & Hafler DA (2010) FOXP3+ regulatory T cells in the 
1012 human immune system. Nat Rev Immunol 10(7):490-500.
1013 146. Wing K, et al. (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 
1014 322(5899):271-275.
1015 147. Ring S, Schafer SC, Mahnke K, Lehr HA, & Enk AH (2006) CD4+ CD25+ regulatory T cells 
1016 suppress contact hypersensitivity reactions by blocking influx of effector T cells into inflamed 
1017 tissue. Eur J Immunol 36(11):2981-2992.
1018 148. Vocanson M, et al. (2010) Inducible costimulator (ICOS) is a marker for highly suppressive 
1019 antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells. J Allergy Clin 
1020 Immunol 126(2):280-289, 289 e281-287.
1021 149. Kish DD, Gorbachev AV, & Fairchild RL (2005) CD8+ T cells produce IL-2, which is required for 
1022 CD(4+)CD25+ T cell regulation of effector CD8+ T cell development for contact 
1023 hypersensitivity responses. J Leukoc Biol 78(3):725-735.
1024 150. Gomez de Aguero M, et al. (2012) Langerhans cells protect from allergic contact dermatitis 
1025 in mice by tolerizing CD8(+) T cells and activating Foxp3(+) regulatory T cells. J Clin Invest 
1026 122(5):1700-1711.
1027 151. El Beidaq A, et al. (2016) In Vivo Expansion of Endogenous Regulatory T Cell Populations 
1028 Induces Long-Term Suppression of Contact Hypersensitivity. J Immunol 197(5):1567-1576.
1029 152. Cavani A, et al. (2003) Human CD25+ regulatory T cells maintain immune tolerance to nickel 
1030 in healthy, nonallergic individuals. J Immunol 171(11):5760-5768.































































1031 153. Vocanson M, et al. (2008) Depletion of human peripheral blood lymphocytes in CD25+ cells 
1032 allows for the sensitive in vitro screening of contact allergens. J Invest Dermatol 128(8):2119-
1033 2122.
1034 154. Martin SF, et al. (2010) T-cell recognition of chemicals, protein allergens and drugs: towards 
1035 the development of in vitro assays. Cell Mol Life Sci 67(24):4171-4184.
1036 155. Gao L, et al. (2010) Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. J 
1037 Dermatol Sci 57(1):51-56.
1038 156. Inoue N, et al. (2010) Association of functional polymorphisms related to the transcriptional 
1039 level of FOXP3 with prognosis of autoimmune thyroid diseases. Clin Exp Immunol 
1040 162(3):402-406.
1041 157. Gandhi R, et al. (2010) Activation of the aryl hydrocarbon receptor induces human type 1 
1042 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 11(9):846-853.
1043 158. Nadeau K, et al. (2010) Ambient air pollution impairs regulatory T-cell function in asthma. J 
1044 Allergy Clin Immunol 126(4):845-852 e810.
1045 159. Shiohara T, Kano Y, Takahashi R, Ishida T, & Mizukawa Y (2012) Drug-induced 
1046 hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and 
1047 management. Chem Immunol Allergy 97:122-138.
1048 160. Takahashi R, et al. (2009) Defective regulatory T cells in patients with severe drug eruptions: 
1049 timing of the dysfunction is associated with the pathological phenotype and outcome. J 
1050 Immunol 182(12):8071-8079.
1051 161. Wang CW, et al. (2018) Randomized, controlled trial of TNF-alpha antagonist in CTL-
1052 mediated severe cutaneous adverse reactions. J Clin Invest 128(3):985-996.
1053 162. Ushigome Y, et al. (2018) Monocytes are involved in the balance between regulatory T cells 
1054 and Th17 cells in severe drug eruptions. Clin Exp Allergy 48(11):1453-1463.
1055 163. Morito H, et al. (2014) Increased ratio of FoxP3+ regulatory T cells/CD3+ T cells in skin 
1056 lesions in drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic 
1057 symptoms. Clin Exp Dermatol 39(3):284-291.
1058 164. Hanafusa T, Azukizawa H, Matsumura S, & Katayama I (2012) The predominant drug-specific 
1059 T-cell population may switch from cytotoxic T cells to regulatory T cells during the course of 
1060 anticonvulsant-induced hypersensitivity. J Dermatol Sci 65(3):213-219.
1061 165. Cardone M, et al. (2018) A transgenic mouse model for HLA-B*57:01-linked abacavir drug 
1062 tolerance and reactivity. J Clin Invest 128(7):2819-2832.
1063 166. Curtsinger JM & Mescher MF (2010) Inflammatory cytokines as a third signal for T cell 
1064 activation. Curr Opin Immunol 22(3):333-340.
1065 167. Curtsinger JM, Lins DC, & Mescher MF (2003) Signal 3 determines tolerance versus full 
1066 activation of naive CD8 T cells: dissociating proliferation and development of effector 
1067 function. J Exp Med 197(9):1141-1151.
1068 168. Talaat RM, Mohamed SF, Bassyouni IH, & Raouf AA (2015) Th1/Th2/Th17/Treg cytokine 
1069 imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. 
1070 Cytokine 72(2):146-153.
1071 169. Guan Q & Zhang J (2017) Recent Advances: The Imbalance of Cytokines in the Pathogenesis 
1072 of Inflammatory Bowel Disease. Mediators Inflamm 2017:4810258.
1073 170. Arend WP (2001) Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of 
1074 interleukin-1 receptor antagonist. Semin Arthritis Rheum 30(5 Suppl 2):1-6.
1075 171. Bayard PJ, Berger TG, & Jacobson MA (1992) Drug hypersensitivity reactions and human 
1076 immunodeficiency virus disease. J Acquir Immune Defic Syndr 5:1237-1257.
1077 172. Clerici M & Shearer GM (1993) A TH1-->TH2 switch is a critical step in the etiology of HIV 
1078 infection. Immunol Today 14(3):107-111.
1079 173. Bonfield TL, Konstan MW, & Berger M (1999) Altered respiratory epithelial cell cytokine 
1080 production in cystic fibrosis. J Allergy Clin Immunol 104(1):72-78.































































1081 174. Bonfield TL, et al. (1995) Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care 
1082 Med 152(6 Pt 1):2111-2118.
1083 175. Scambler T, Holbrook J, Savic S, McDermott MF, & Peckham D (2018) Autoinflammatory 
1084 disease in the lung. Immunology.
1085 176. Chessman D, et al. (2008) Human leukocyte antigen class I-restricted activation of CD8+ T 
1086 cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 
1087 28(6):822-832.
1088 177. Walsh JS, Reese MJ, & Thurmond LM (2002) The metabolic activation of abacavir by human 
1089 liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem Biol Interact 
1090 142(1-2):135-154.
1091 178. Wu Y, et al. (2006) Activation of T cells by carbamazepine and carbamazepine metabolites. J 
1092 Allergy Clin Immunol 118(1):233-241.
1093 179. Wei CY, Chung WH, Huang HW, Chen YT, & Hung SI (2012) Direct interaction between HLA-B 
1094 and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy 
1095 Clin Immunol 129(6):1562-1569 e1565.
1096 180. Pearce RE, Uetrecht JP, & Leeder JS (2005) Pathways of carbamazepine bioactivation in vitro: 
1097 II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. 
1098 Drug Metab Dispos 33(12):1819-1826.
1099 181. Pearce RE, Vakkalagadda GR, & Leeder JS (2002) Pathways of carbamazepine bioactivation in 
1100 vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 
1101 3-hydroxylated metabolites. Drug Metab Dispos 30(11):1170-1179.
1102 182. Chen WT, et al. (2018) The Function of HLA-B*13:01 Involved in the Pathomechanism of 
1103 Dapsone-Induced Severe Cutaneous Adverse Reactions. J Invest Dermatol 138(7):1546-1554.
1104 183. Vyas PM, Roychowdhury S, & Svensson CK (2006) Role of human cyclooxygenase-2 in the 
1105 bioactivation of dapsone and sulfamethoxazole. Drug Metab Dispos 34(1):16-18.
1106 184. Roychowdhury S, Vyas PM, Reilly TP, Gaspari AA, & Svensson CK (2005) Characterization of 
1107 the formation and localization of sulfamethoxazole and dapsone-associated drug-protein 
1108 adducts in human epidermal keratinocytes. J Pharmacol Exp Ther 314(1):43-52.
1109 185. Cribb AE, Spielberg SP, & Griffin GP (1995) N4-hydroxylation of sulfamethoxazole by 
1110 cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole 
1111 hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 23(3):406-414.
1112 186. Mannargudi B, McNally D, Reynolds W, & Uetrecht J (2009) Bioactivation of minocycline to 
1113 reactive intermediates by myeloperoxidase, horseradish peroxidase, and hepatic 
1114 microsomes: implications for minocycline-induced lupus and hepatitis. Drug Metab Dispos 
1115 37(9):1806-1818.
1116 187. Iverson SL & Uetrecht JP (2001) Identification of a reactive metabolite of terbinafine: insights 
1117 into terbinafine-induced hepatotoxicity. Chem Res Toxicol 14(2):175-181.
1118 188. Nicoletti P, et al. (2017) Association of Liver Injury From Specific Drugs, or Groups of Drugs, 
1119 With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. 
1120 Gastroenterology 152(5):1078-1089.
1121 189. Usui T, et al. (2018) HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from 
1122 Human Donors. Chem Res Toxicol 31(10):1022-1024.
1123 190. Liu ZC & Uetrecht JP (2000) Metabolism of ticlopidine by activated neutrophils: implications 
1124 for ticlopidine-induced agranulocytosis. Drug Metab Dispos 28(7):726-730.
1125 191. Konvinse KC, et al. (2019) HLA-A*32:01 is strongly associated with vancomycin-induced drug 
1126 reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol 144(1):183-192.
1127
Page 73 of 73 Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
